UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-KSB

[X] ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2002

[ ]  TRANSITIONAL  REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
     ACT OF 1934.

                          HEALTH DISCOVERY CORPORATION
                          ----------------------------
               (Name of small business corporation in its charter)

                 TEXAS                                 74-3002154
----------------------------------         ------------------------------------
(State or other jurisdiction                      (I.R.S. Employer
 of incorporation)                               Identification No.)
1116 South Old Temple Road
Lorena, Texas                                              76655
----------------------------------         ------------------------------------

Issuer's telephone number (512) 583-4500
Securities registered under Section 12(g) of the Exchange Act:
COMMON STOCK, NO PAR VALUE PER SHARE
(Title of class)

Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports, and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [ ]

Check if there is no disclosure of delinquent filers in response to Item 405 of Regulation S-B contained in this form, and no disclosure will be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-KSB or any amendment to this Form 10K-SB. [X]

State issuer's revenues for its most recent fiscal year. $ 0.00

State the aggregate market value of the voting stock held by non-affiliates computed by reference to the price at which the stock was sold, or the average bid and asked prices for such stock, as of a specified date within the past 90 days. $21,688,360 as of February 27, 2004.

State the number of shares outstanding of each of the issuer's classes of common

equity, as of the latest practicable date. 67,776,128

Transitional Small Business Disclosure Format (Check one): Yes   , No X
                                                             ---     ---


PART I

ITEM 1. DESCRIPTION OF BUSINESS

OUR HISTORY

We were organized under the name Direct Wireless Communications, Inc., in April 2001 by Direct Wireless Corporation, which licensed to us its technology for a wireless telephone. In October 2001, Direct Wireless Corporation, then our sole shareholder, pursuant to an effective registration statement under the Securities Act of 1933, distributed its entire holdings of our common stock as a stock dividend to its shareholders. As a result of the dividend, Direct Wireless Corporation ceased to own any of our equity securities. The negative events that occurred over the next several years in the communications industry made it difficult for us to fund the advancement of our communication platform. As a result, we made the decision to strategically change the overall direction of our intended business activities.

On September 25, 2003, we acquired all of the assets of The Barnhill Group,
LLC., which was owned by Stephen D. Barnhill, M.D. Dr. Barnhill is a physician trained in laboratory medicine and clinical pathology. He is a pioneer in the development of artificial intelligence and pattern recognition computational techniques used in medicine, genomics, proteomics, diagnostics and drug discovery. Following the acquisition, Dr. Barnhill became our Chief Executive Officer and Chairman of our Board of Directors. Also, immediately following our acquisition of The Barnhill Group, our licensing rights to the telecommunications technology previously granted by Direct Wireless Corporation were automatically terminated under the terms of the license agreement. Additionally, at that time, all payments due to Direct Wireless Corporation were terminated.

Subsequently, we amended our charter to change our name to Health Discovery Corporation. Direct Wireless Communications (DWCM.OB) officially became Health Discovery Corporation on November 6, 2003, at which time the new trading symbol (HDVY.OB) became effective. On August 29, 2003, we signed a binding letter of agreement to acquire the assets of Fractal Genomics, a company founded by Mr. Sandy Shaw with patented Fractal Genomics Modeling software. Fractal Genomics utilized its technology to find, link and model patterns of similarity hidden in large amounts of information, such as the clinical databases used for diagnostic and drug discovery. Fractal Genomics has applied its technology to protein and pathway discovery in leukemia and lung development, which could lead to the identification of novel proteins that could be used to develop diagnostic markers and drug targets. Our acquisition of Fractal Genomics was completed December 30, 2004. Mr. Shaw currently serves as our Vice President, Fractal Technology.

2

OUR MARKET

Developing and evaluating new drugs and medical therapies in less time and at lower cost is of enormous potential benefit for modern healthcare. Genuinely new products must pass a series of both in-vitro and in-vivo testing in order to demonstrate their safety and effectiveness for a specific clinical application. Historically, the endpoints of these trials were "traditional" ones tied to the actual disease being evaluated, such as a decrease in mortality or an objective/semi-objective decrease in clinical symptoms associated with the condition. In the last 10 to 15 years, there has been a move by the U.S. Food and Drug Administration (FDA) to incorporate other endpoints, including genes that are biomarkers for the existence or absence of a particular disease, which are nontraditional findings that are related to the presence or absence of disease. Examples of successful application of biomarker data to therapeutic evaluation include the drugs Betaseron for use against multiple sclerosis and Herceptin in the treatment of breast cancer.

The FDA began an initiative in 1987 designed to expedite approval for drugs. Initially utilized for drugs that would combat the devastating AIDS epidemic, these initiatives measured alternative factors such as biomarkers to essentially evaluate the effectiveness of new therapeutics for diseases such as AIDS.

Our goal is to leverage the FDA's expedited approval process by producing more relevant and predictable biomarkers for drug discovery. By speeding up approval, new and better medicines and diagnostic markers can be developed for patients worldwide.

Biomarkers have long played a significant role in drug discovery and development, but recent advances have signaled the potential for significant deepening of their role in terms of both broader application within particular stages of the process and application across a broader spectrum of functions. Even before the recent resurgence of interest in the subject, single-analyte biomarkers had already made significant impacts on clinical studies as surrogates for clinical endpoints. Recent advances in discovery of multi-component biomarkers and single-molecule markers derived from them show promise of providing greatly improved clinical sensitivity and specificity over their pre-genomic forbears.

One major difficulty with biomarker discovery relates to the accessibility of patient samples. Whereas tissues from animal models are usually readily available, human tumor specimens and human body fluid specimens are often unavailable or inaccessible for most common diseases of major commercial interest.

Another major difficulty is developing new mathematical tools capable of handling the analysis of the terabytes of information being generated by the genomic and proteomic analysis of clinical specimens that must be sifted through to identify the key biomarkers that will provide important clues leading to the identification of new diagnostic and drug targets, not only for cancer but for other medically and commercially important diseases as well.

An additional difficulty in commercialization of newly discovered biomarkers is establishing relationships at large US medical and cancer centers to validate the results in a clinical setting. Validation studies are required to ensure that the markers are valid for a large population. The validation process is characterized by proving the efficacy of the newly discovered biomarkers in larger sample sets. Access to these prestigious institutions for validation studies can often be difficult to arrange.

3

Using our established relationships with top US medical and cancer centers and our recent acquisition fractal genomics computational technologies, our goal is to overcome the difficulties encountered with biomarker discovery and become the first company, to our knowledge, to perform the total process of "first-phase" discovery by identifying a particular clinical problem to be solved and performing the entire process leading to the identification of the genes or proteins (called biomarkers), and the relationships among them (called pathways) that are relevant to the solution of the medical problem as described below. This process will consist of an assessment of the clinical problem, the determination of the clinical trial set-up (the number of patients and what medical conditions they represent), the proper selection and procurement of high quality specimens for analysis, an analytical evaluation of the specimens through laboratory tests to produce the clinical data, and the mathematical evaluation of the data using our proprietary pattern recognition techniques such as fractal geometric modeling to produce an accurate determination of the relevant genes and proteins and the manners in which they interact. Once we discover these new biomarkers and pathways, we intend to immediately file patent applications to protect the discoveries such as with the patents filed for our Leukemia discovery.

These patent, protected biomarkers and pathways represent the products of our company. After our discovery is patent protected, the process of selling or licensing the newly discovered biomarkers and pathways will begin. The information will then be sold or licensed to diagnostic companies for development into new state-of-the-art diagnostic assays and the same information will be sold or licensed to pharmaceutical companies for further development into the next generation of therapeutic targets.

Intellectual property is a key asset in diagnostic and drug discovery. Our products will be based on intellectual property, which includes the discovered biomarkers and pathways produced through our own internal research programs, as well as joint discovery efforts with academic institutions, diagnostic and pharmaceutical companies worldwide.

Our discovery process has already been shown to lead to the identification of biomarkers and pathways in leukemia and lung development and we hope will be instrumental in diagnosing and treating patients with devastating diseases like cancer, heart disease, obesity and AIDS.

OUR TECHNOLOGIES

Using our technologies, we intend to become the first company to perform the total process of identifying a particular clinical medical problem to be solved and performing the entire process leading to the identification of the genes or proteins (called biomarkers), and the relationships among them (called pathways), that are relevant to the solution of the medical problem. This process will consist of an assessment of the clinical problem, the determination of the clinical trial set-up (the number of patients and what medical conditions they represent), the proper selection and procurement of high quality specimens for analysis, an analytical evaluation of the specimens through laboratory tests to produce the clinical data, and the mathematical evaluation of the data using pattern recognition techniques and fractal geometric modeling to produce an accurate determination of the relevant genes and proteins and the manners in which they interact.

Once we discover new biomarkers and pathways, we intend to file patent applications to protect

4

the discoveries. These patent protected biomarkers and pathways represent the products of our company. After the discovery is patent protected, the process of selling or licensing the newly discovered biomarkers and pathways begins. The information will then be sold or licensed to diagnostic companies for development into diagnostic assays and the same information will be sold or licensed to pharmaceutical companies for further development as potential drug targets.

Our products will be based on intellectual property, which includes the discovered biomarkers and pathways produced through our own internal research programs, as well as joint discovery efforts with diagnostic and pharmaceutical companies worldwide. Newly discovered and patent protected biomarkers and pathways will then be sold or licensed to diagnostic and pharmaceutical companies for further development into diagnostic tests or therapeutic agents. Our discovery process has been shown to lead to the identification of biomarkers and pathways in leukemia and lung development and will be instrumental in diagnosing and treating patients with devastating diseases like cancer, heart disease, obesity and AIDS.

Our goal is to develop a product line of newly discovered biomarkers and pathways, which will include human genes and genetic variations, as well as gene, protein, and metabolite expression differences. In drug discovery, biomarkers can help elicit disease targets and pathways and validate mechanisms of drug action. They may also be pharmacodynamic indicators of drug activity, response and toxicity for use in clinical development.

We will provide pharmaceutical and diagnostic companies with all aspects of "first phase" diagnostic and drug discovery from expert assessment of the clinical dilemma through proper selection and procurement of high quality specimens. We will then apply our proprietary analytical evaluation methods and state-of-the-art computational analysis to produce relevant and accurate clinical data, producing accurate biomarker and pathway discoveries, resulting in patent protection of our biomarker discoveries for future development.

The recent acquisition of Fractal Genomics brought us a fully functional patent protected computational tool, which is now known as the Health Discovery Fractal Genomics (HDFG) technology. This technology is designed to study complex biological networks such as genomic and proteomic pathways in disease. A complex network can be made up of genes or proteins inside a living organism. HDFG uses this new approach toward modeling network behavior to rapidly generate diagrams and software simulations that facilitate prediction and analysis of genomic and proteomic data to facilitate diagnostic and drug discovery.

The HDFG modeling process starts out by creating a special mathematical surface (the HDFG surface) where every point on the surface can be used to generate a network model with varying degrees of scale-free and fractal properties.

Using user-supplied clinical data, models which best match the behavior of each node are selected and represented by a point on the HDFG surface. These point-models are then linked, compared, and combined to generate diagrams, which reflect the behavior of genes or proteins in the entire network

The end result of the HDFG modeling process is biomarker and pathway discovery diagrams that represent nodes in the network and directions of causality or "flow" through the network such as

5

which genes or proteins are "turning-on" or "turning -off" other precursor and successor genes or proteins in the biological system. HDFG derived diagrams expedite forecasting, analysis, and study of complex system behavior by clearly displaying all hubs, links, and flow in the network. With this knowledge, diagnostic companies can use the newly identified biomarkers to create state-of-the-art tests to identify key genes and proteins involved in certain diseases and pharmaceutical companies can explore new therapeutic drug targets designed to interrupt ("turn-off") genes or proteins with undesirable effects or promote ("turn-on") genes or proteins with desirable effects.

In addition, as a result of the Fractal Genomics acquisition, we are preparing to begin validation studies, at MD Anderson Cancer Center, of the recently discovered and patent protected set of leukemia genes, discovered using the newly acquired HDFG technique, which was shown to separate ALL-T-cell leukemia from ALL-B-cell leukemia with 100% accuracy. This gene set, now our intellectual property, was originally presented to the medical and scientific world by Dr. Herbert Fritsche, Chairman of our Scientific Advisory Board, a world-renowned, expert in cancer markers and Professor at MD Anderson Cancer Center, at 31st Meeting of the International Society for Oncodevelopmental Biology and Medicine (ISOBM) in Edinburgh, United Kingdom.

To date, our HDFG technology has been successfully used to analyze databases from MD Anderson Cancer Center, St. Jude Children's Hospital and the Alvin J. Siteman Cancer Center at Washington University. We recently entered significant collaborations for biomarker discovery with MD Anderson Cancer Center, Stanford University and the University of Miami and will be using our HDFG technology to analyze databases relating to prostate cancer, leukemia, AIDS related dementia, and lymphatic insufficiency. All of these biomarker discovery collaborations brought Health Discovery Corporation contracts with either joint ownership in the discovery or the right to a world wide exclusive license to commercialize the discovery

OUR CORPORATE STRATEGY

Our goal is to develop a product line of newly discovered biomarkers and pathways, which will include human genes and genetic variations, as well as gene, protein, and metabolite expression differences. In drug discovery, biomarkers can help elicit disease targets and pathways and validate mechanisms of drug action. They may also be pharmacodynamic indicators of drug activity, response and toxicity for use in clinical development.

We intend to provide pharmaceutical and diagnostic companies with all aspects of "first phase" diagnostic and drug discovery from expert assessment of the clinical dilemma through proper selection and procurement of high quality specimens. We will then apply our proprietary analytical evaluation methods and state-of-the-art computational analysis to produce relevant and accurate clinical data, producing accurate biomarker and pathway discoveries, resulting in patent protection of our biomarker discoveries for future development.

"First Phase" biomarker discovery is based on the belief that in order to discover the most clinically relevant biomarkers, the computational component must begin at the inception of the clinical dilemma to be solved. This pathway includes several critical levels of decision-making all of which are part of our business strategy.

6

THE FIRST LEVEL OF DISCOVERY IS ASSESSMENT OF THE CLINICAL DILEMMA.

Is the desired biomarker or pathway to be identified related to early diagnosis, metastasis, treatment response or some other aspect of a given disease process? Based on the clinical question to be answered along with the incidence, prevalence and nature of the particular disease, we will establish a clinical study with the appropriate number of necessary specimens. We expect that these studies will provide statistically significant results once the biomarker and pathway discovery is completed.

THE SECOND LEVEL OF DISCOVERY IS THE PROPER IDENTIFICATION AND PROCUREMENT OF THE MOST RELEVANT AND PROFESSIONALLY COLLECTED CLINICAL SPECIMENS.

Based on the clinical dilemma to be solved, does the appropriate clinical trial require blood, serum, aspirate fluid, tissue or some other clinically relevant specimen? Once the correct decision is made, we will contractually procure the specimens necessary for the discovery from highly reputable institutions, where we believe proper collection and informed consent are completed under the strictest scientific protocol.

THE THIRD LEVEL OF DISCOVERY IS THE ANALYTICAL COMPONENT.

The clinical specimens must then be analyzed and converted into relevant clinical data. We will determine which analytical method is appropriate for the most successful biomarker and pathway discovery. The techniques we currently expect to use include mass spectroscopy, MALDI, SELDI, DNA methylation, gene chip analysis, 2-D Gel Electrophoresis, as well as other proprietary techniques developed by companies and academic institutions with which we have relationships. We will constantly monitor improvements in these techniques worldwide.

THE FOURTH LEVEL OF DISCOVERY IS THE COMPUTATIONAL COMPONENT.

The data generated from the analytical component must then be computationally analyzed for the discovery of new biomarkers, patterns among those biomarkers and causality pathways. We will decide which of the current leading computational algorithms, such as our HDFG techniques, are best suited to solve the particular clinical dilemma in question. The data is then computationally analyzed, and the new biomarkers and pathways are discovered and patent protected.

THE FIFTH LEVEL IS DEFINING THE CLINICAL VALIDITY AND UTILITY OF DISCOVERED BIOMARKERS.

Biomarkers uncovered through the four stages of discovery will be subsequently validated independently in larger, clinically relevant populations. Clinical validity of a biomarker is confirmed by its presence in the clinical condition in question and its ability to differentiate one disease state from another, or a diseased state from a healthy state. We hope that markers validated by our processes will provide: vastly improved diagnostic capabilities; may identify potential therapeutic targets for pharmaceutical intervention (e.g. membrane signaling proteins and inhibitors); and markers suitable for monitoring disease progression following therapeutic intervention. Application of clinically validated biomarkers in such a manner will result in improved individual patient care and the advancement of the field of personalized medicine.

7

This unique approach to biomarker discovery and its additional validation in relevant clinical samples advances the commercial potential of biomarkers we uncover to diagnostic and therapeutic partners. Integration of the five levels of biomarker discovery results in improved efficiencies in translation of this information into commercial and medically valuable products.

OUR STRATEGIC AGREEMENTS

In keeping with our corporate goal of building strong partnerships for biomarker discovery, we have signed four biomarker discovery agreements in less than five months with strong academic centers of excellence in the United States, including MD Anderson Cancer Center, Stanford University and the University of Miami. All of these agreements include either joint ownership in any biomarker or pathway discovered or rights to an exclusive worldwide license to our discovery. Once we secure a contract with an academic institution for biomarker and pathway discovery with commercialization rights, we begin negotiating these commercialization rights to our discoveries with diagnostic and pharmaceutical companies worldwide.

In October 2003 we signed our first Agreement with M.D. Anderson Cancer Center. With this agreement we will analyze a gene expression database to identify new biomarkers and pathways involved in leukemia. Under the terms of the agreement, M.D. Anderson, has granted us a first option to obtain an exclusive worldwide royalty-bearing commercial license to commercialize any discovered biomarkers or pathways we identify.

In January 2004 we entered into our second Biomarker and Pathway Discovery Agreement with The University of Texas, M.D. Anderson Cancer Center in Houston Texas. Under the terms of the agreement, The University of Texas, M.D. Anderson Cancer Center, has again granted us a first option to obtain an exclusive worldwide royalty-bearing commercial license to commercialize any discovered prostate cancer biomarkers or pathways identified by us utilizing our proprietary HDFG computational techniques. This second collaboration with MD Anderson Cancer Center will give us access to a new systems biology approach for data analysis for new biomarker and pathway discovery in prostate cancer. We intend to use the findings of this study to develop new diagnostic approaches for prostate cancer and improve the clinical management of these patients. U.S. Cancer Statistics: 2000 Incidence recently released by the Department of Health and Human Services shows that prostate cancer is the leading cancer overall in men in the United States and according to the National Institutes of Health, in 1997, the estimated number of new cases of prostate cancer in the United States is 209,900, and the estimated number of deaths from the disease is 41,800. The current market for prostate cancer testing with PSA, the biomarker currently used to diagnose prostate cancer, is estimated to be approximately $350 million annually around the world.

In March 2004 we entered into an agreement with Stanford University to use our proprietary and patent protected HDFG computational techniques to identify new patterns of biomarkers in lymphatic insufficiency and its response to therapeutic lymphangiogenesis. According to the agreement, ownership of Research Program Inventions conceived, discovered or reduced to practice under the Research Program will be determined based on inventorship. As such, any invention discovered using our analytical tools on this Stanford database will be jointly owned by Stanford and us.

8

According to the World Health Organization, lymphedema affects 250 million people worldwide. Others estimate that one in every twenty-five will suffer from some form of lymphedema during their lifetime. The M.D. Anderson Cancer Center in Houston, Texas reports that approximately 15% of all women with breast cancer will develop lymphedema over the course of their lifetime and that lymphedema resulting from prostate cancer is on the rise.

In March 2004 we signed an Agreement with The University of Miami to use Health Discovery Corporations proprietary and patent protected HDFG computational techniques to identify new patterns of biomarkers in AIDS Related Dementia. It is hoped that this newly discovered information will allow physicians to better understand the pathogenesis of AIDS Related Dementia and will assist in the diagnosis and treatment of this devastating disease. Under the terms of the Agreement, The University of Miami has granted us joint ownership on any product, invention, discovery or new use arising out of or developed utilizing our unique computational methods.

Estimates of the incidence of HIV-associated dementia vary, depending on the definition of dementia being used. Researchers from the John Hopkins University have estimated that 15% of HIV-infected people may develop dementia and that 30% may show some signs of neurological impairment.

In addition, as a result of the Fractal Genomics acquisition, we are preparing to begin validation studies, at MD Anderson Cancer Center, of the recently discovered and patent protected set of leukemia genes, discovered using the newly acquired HDFG technique, which was shown to separate ALL-T-cell leukemia from ALL-B-cell leukemia with 100% accuracy. This gene set, now our intellectual property, was originally presented to the medical and scientific world by Dr. Herbert Fritsche, Chairman of our Scientific Advisory Board, a world-renowned, expert in cancer markers and Professor at MD Anderson Cancer Center, at 31st Meeting of the International Society for Oncodevelopmental Biology and Medicine (ISOBM) in Edinburgh, United Kingdom.

ITEM 2. DESCRIPTION OF PROPERTY.

We do not own any real property. Our administrative office is located at the personal office of our Chief Administrative Officer, Robert S. Braswell IV 1116 S. Old Temple Road Lorena, Texas 76655, telephone no. (512) 583-4500. Our principal executive office is currently located at 6709 Waters Avenue, Savannah, Georgia 31406, telephone no. (866) 953-9031.

ITEM 3. LEGAL PROCEEDINGS.

None.

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.

On October 1, 2003, the holders of 41,541,567 shares of the 59,751,128 shares of outstanding common stock (69.5%), by written consents, approved the amendment of our Articles of Incorporation to change our name from Direct Wireless Communications, Inc., to Health Discovery Corporation.

9

PART II

ITEM 5. MARKET FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS.

(a) Our common stock is traded on the OTC Bulletin Board; symbol HDVY.OB. The range of bids for our common stock, as reported on Bloomberg.com during each quarter of the last two fiscal years. was as follows.

                                 HIGH BID       LOW BID
                                 --------       -------

First Quarter 2002                 $.47          $.13

Second Quarter 2002                $.21          $.04

Third Quarter 2002                 $.14          $.06

Fourth quarter 2002                $.10          $.02

First quarter 2003                 $.07          $.025

Second quarter 2003                $.045         $.02

Third quarter 2003                 $.15          $.02

Fourth Quarter 2003                $.60          $.06

(b) At December 31, 2003, there were 322 holders of record of our common stock.

(c) We have not paid any cash dividends since inception.

ITEM 6. PLAN OF OPERATION.

We have not realized any earned income since inception. While we have entered into agreements to perform analyses of clinical data using our computational technologies, we will earn income from those efforts after the identification and patenting of new biomarkers. We did, however, secure both joint ownership rights and/or first options for worldwide exclusive rights to our discoveries in these agreements. We intend to fund our operations though a private offering of our common stock under rules providing exemptions for such offerings.

ITEM 7. FINANCIAL STATEMENTS.

Financial statements appear at pages F1 through F9 of this Report.

ITEM 8. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE.

10

None.

PART III

ITEM 9. DIRECTORS, EXECUTIVE OFFICERS, PROMOTERS AND CONTROL PERSONS; COMPLIANCE WITH SECTION 16(a) OF THE EXCHANGE ACT.

Our executive officers and directors are:

NAME                         AGE    POSITION

Stephen D. Barnhill, M.D.     44    Chief Executive Office Chairman of the Board

David Cooper, M.D., Ph.D.     49    President and Chief Medical Officer

Robert S. Braswell, IV        48    Chief Administrative Officer, Director,
and Treasurer                       Secretary

Sandy Shaw                    49    Vice President Fractal Technologies

Joe Fanelli                   42    Director of Corporate Development

The present directors were appointed in May 2001 and November 2003 and will serve until their successors are elected at an annual meeting of the shareholders. Thereafter directors will serve a term of one year.

STEPHEN D. BARNHILL, M.D., CHIEF EXECUTIVE OFFICER AND CHAIRMAN OF THE BOARD AND MEDICAL DIRECTOR of Health Discovery Corporation is a physician trained in Laboratory Medicine and Clinical Pathology. He is a Pioneer in the development and use of Artificial Intelligence, Pattern-Recognition and Computational Techniques used in Medicine, Genomics, Proteomics, Diagnostics and Drug Discovery.

Dr. Barnhill is or has been a Fellow of the American College of Physician Inventors, the American College of International Physicians, the American Medical Association, the American College of Physician Executives, the American Association of Artificial Intelligence, the American College of Managed Care Medicine, the Association of Clinical Scientists, the American Society of Contemporary Medicine and Surgery, the American Society of Law, Medicine and Ethics, the Southern Medical Society, the American Federation for Clinical Research and the National Federation of Catholic Physicians.

Dr. Barnhill founded the Barnhill Clinical Laboratories in 1988 and served as Chairman, CEO, President and Medical Director. This Laboratory was later acquired by Corning-Metpath in 1989 and after the acquisition he served as Medical Director of this Clinical Laboratory until 1992. This Clinical Laboratory, now owned by Quest Diagnostics, continues to be the largest and busiest Clinical Laboratory in the Savannah Georgia area.

11

In 1992, Dr. Barnhill founded National Medical Specialty Laboratories and served as Chairman, CEO, President, and Medical Director. This Research Laboratory was founded to utilize pattern-recognition mathematics and artificial intelligence techniques in cancer diagnosis. Dr. Barnhill is an inventor on the very first patents issued by the United States Patent and Trademark Office for the use of neural networks in medicine. This company was acquired by Horus Therapeutics; a New York based Pharmaceutical Company. Dr. Barnhill served as Executive Vice-President and Chairman of the Scientific Advisory Board for Horus Therapeutics until 1998. Johnson & Johnson later acquired the Horus patents invented by Dr. Barnhill.

In 1999, Dr. Barnhill founded and served as Chairman, President and CEO of Barnhill BioInformatics, Inc. Barnhill BioInformatics, Inc. later became Barnhill Genomics, Inc. and BioWulf Technologies, LLC and raised over $13.5 Million in Private Placement funding. The primary focus of these Companies was to utilize the next generation of artificial intelligence and pattern-recognition techniques, known as support vector machines, to identify genes that cause cancer. Dr. Barnhill is the sole inventor on the very first patents issued by the United States Patent and Trademark Office for the use of support vector machines in medicine. These Companies have six issued patents in the United States, Europe and other foreign countries and approximately thirty pending patents worldwide. From the summer of 2000 until he organized The Barnhill Group L.L.C., in the summer of 2003, Dr. Barnhill was not engaged in any professional activities as the result of a non-compete agreement signed by Dr. Barnhill when he left the employment of Barnhill Genomics, Inc.

DAVID COOPER, M.D., PH.D., became our PRESIDENT AND CHIEF MEDICAL OFFICER and a member of the Board of Directors on October 30, 2003. For the past four years Dr. Cooper has devoted his time to significant national and international work aimed at bringing the new technologies of genomics and molecular biology closer to patient care. In this time he consulted and held positions with a number of biotechnology and genomics companies including Qiagen (Hilden, Germany) Sequenom, Inc. (San Diego, CA and Hamburg, Germany), Samsung Advanced Institute of Technology (Suwon, Korea), DynaMetrix (Stockholm, Sweden), Pluvita Corporation (Bethesda, MD), diaDexus (Santa Clarita, CA), SomaLogic (Boulder, CO), LumiCyte (Freemont, California), GeneLogic (Gaithersburg, MD), NimbleGen Systems Iceland, LLC. (Reykjavik, Iceland), Gentra Systems (Minneapolis, Minnesota). and The Marshfield Clinic (Marshfield, WI). Currently besides continuing as President of his own consulting group, David L. Cooper and Associates, Dr. Cooper is President and a member of the Board of Directors of Healthcare Discovery Corporation (HDVY) (Savannah, Georgia). In addition he serves on the Scientific Advisory Boards of Gentra Systems (Minneapolis, Minnesota) and Specialty Laboratories (Santa Monica, California).

Dr. Cooper served as the former Chief Science Officer and Chief Operating Officer of Quest Diagnostics, Nichols Institute, in San Juan Capistrano, California. While at Quest Diagnostics, Dr. Cooper coordinated the Nichols Institute's move to an ISO 9001 company, expanded their HIV and genetic testing, and reorganized the Nichols Institute Research and Test Development efforts into a clinical specialty focus. Dr. Cooper also assisted in opening new markets in Asia, South America and Europe for Quest Diagnostics, Nichols Institute. He served as Vice President and Chief Science Officer at diaDexus in Santa Clara, California and Chief Medical Officer

12

of NimbleGen Systems. While at NimbleGen Systems, Dr. Cooper established NimbleGen Systems of Iceland, LLC, which currently manufactures custom DNA arrays and related services to the scientific research marketplace worldwide. Dr. Cooper also served as Senior Scientific Advisor to Visible Genetics, Inc. of Toronto, Canada, where he assisted with the development of the FDA approved Tru-Gene HIV genotyping system.

In academia, Dr. Cooper held tenured pathology faculty positions at Duke University Medical Center and the University of Pittsburgh Medical Center. While at the University of Pittsburgh, he founded the first division of Molecular Pathology in the United States, assisted in founding and served as the first chair of the Association for Molecular Pathology, and was editor and founder of Molecular Diagnosis -- a journal devoted to the understanding of human disease through the clinical application of molecular biology. His academic honors include the prestigious Lichfield Lectureship, Oxford University, Oxford, England. Dr. Cooper is the author of more than 100 scientific and medical publications in molecular diagnostics and the development of novel gene therapies which were supported by numerous grants including grants from the National Institutes of Health, the American Cancer Society and the Department of Defense Breast Cancer Initiative.

ROBERT S. BRASWELL IV is our CHIEF ADMINISTRATIVE OFFICER, SECRETARY AND TREASURER. Mr. Braswell served as our President from April 2001 until the acquisition of the Barnhill Group LLC, when he assumed his current positions. As its President, he guided the creation of Direct Wireless Communications Inc. (DWCI) and oversaw all administrative functions for both DWCI and Direct Wireless Corporation. Mr. Braswell served as President of Direct Wireless Corporation since December 1999 and a member of its Board of Directors since January 1999. Prior to holding these positions, Mr. Braswell was an independent businessman engaged in business evaluations, real estate development, home construction while running a working ranch operation. His administrative experience comes from eighteen years experience in the common carrier freight business, working for Central Freight Lines, Inc. from 1974-1992. Mr. Braswell graduated from the University of Houston in 1983 with a Bachelor of Business Administration in Organizational Behavior Management.

SANDY SHAW - VICE PRESIDENT, FRACTAL TECHNOLOGY. Mr. Shaw has been a computer scientist and software engineer for over 20 years, working at companies and institutions such as Bell Labs, Lockheed Electronics, University of Hawaii, and University of California, San Francisco, where he was a postgraduate researcher in the field of bioinformatics. Mr. Shaw began studying dynamical systems theory (chaos theory) as part of his graduate research in physics in the late seventies. This later led to development of a fractal data compression algorithm for commercial use in 1988, which in turn led to his current research in data analysis and modeling using fractal surfaces.

From 1997 until 2000, Mr. Shaw did consulting work in contract programming where he developed software for fractal-based methods of analyzing large datasets.From 2000 until 2001he was a bioinformatics researcher for the University of California, San Francisco, testing fractal-based analysis methodology for use in gene expression analysis. Mr. Shaw founded Fractal Genomics in 2001 in order to extend and commercialize this research. Mr. Shaw received his B.S. in Physics from University of Houston in 1976 and his M.S. ABD in Physics from SUNY at Stony Brook in 1978

13

JOE FANELLI - DIRECTOR OF CORPORATE DEVELOPMENT. Mr. Fanelli brings to our company extensive experience in strategic planning, as well as business and product development in the biotechnology arena. Specifically, Mr. Fanelli has been in executive management positions for more than 20 years, including Beckman Instruments, which was acquired by SmithKline. He then joined Cetus Corporation as Director and General Manager of their Instrument Division which was acquired three years later, along with the PCR amplification technology, by Perkin Elmer. Thereafter, Mr. Fanelli served at the Vice President level of Marketing, Sales and Business Development at emerging growth companies in the biotechnology market sector including American Bionetics, Cangene Corporation, Microgenics Corporation, Quantum Biotechnologies 1997-1999, Base 4 Bioinformatics 1998-2000 and Structural Bioinformatics 2000-2002. He participated in the acquisition of two companies and played a key role in starting and growing multi-million dollar biomedical research companies. In 2002 Mr. Fanelli started the, Lighthouse Consulting Group whose expertise is the commercial focus on emerging/converging drug discovery (especially genomics), biotech and diagnostic technologies. Specializing in business development, assessment, planning, beta site testing & market introduction of advanced proteomic and bioinformatic solutions. Mr fanelli joined Health Discovery Corporation in November 2003 to lead our Corporate Development efforts. He holds a B.A in Biology and a Masters Degree in Biological Sciences from California State University

SCIENTIFIC ADVISORY BOARD Our executive officers, directors and senior management are supported and enhanced by the technical expertise provided by members of our Scientific Advisory Board. We believe that the experience, expertise and contacts of the members of our Scientific Advisory Board will facilitate strategic alliances, customer license agreements and other collaborative arrangements that will benefit our company.

HERBERT A. FRITSCHE, M.D. - Chairman. Dr. Fritsche is a professor of Laboratory Medicine and Chief of the Clinical Chemistry Section at The University of Texas, M.D. Anderson Cancer Center in Houston, Texas. During his 35 years at M.D. Anderson Cancer Center, Dr. Fritsche focused his research activities on the development and validation of cancer diagnostics. Dr. Fritsche participated in the validation and FDA clearance process for every commercial serum tumor marker product currently in use in the United States. He served as President of the Clinical Ligand Assay Society (CLAS) and on various committees for both the CLAS and the American Association for Clinical Chemistry (AACC).

Dr. Fritsche is a fellow of the National Academy of Clinical Biochemistry and was awarded the National Award for Contributions in Education by the AACC; the Outstanding Clinical Chemist Award by the Texas Section, AACC; a Dean's Excellence Award for the University of Texas Graduate School of Biomedical Science; a Distinguished Scientist Award from the CLAS; and the Johnson and Johnson Award for Outstanding Research and Contributions to Clinical Biochemistry from the National Academy of Clinical Biochemistry. Dr. Fritsche currently serves on the Expert Panel for developing Tumor Marker Practice Guidelines for the American Society of Clinical Oncology, and the Laboratory Practice Guidelines Committee for the National Academy of Clinical Biochemistry. Dr. Fritsche also serves as a consultant/advisor to the National Cancer Institute and other international diagnostic companies and biotech start-up companies and serves on the editorial board of six international scientific journals.

14

ISABELLE GUYON, PH.D. Dr. Guyon is an internationally recognized expert in statistical data analysis, pattern recognition and machine learning. She is an acknowledged leader in her field serving as an expert with the European Commission to review grant proposals and serves as Vice-President of the International Unipen Foundation. While Dr. Guyon was a Principle Investigator at AT&T Bell Labs, she pioneered applications of neural networks to handwriting recognition for pen computers. In addition, while collaborating with Bernhard Boser and Vladimir Vapnik, she invented the Support Vector Machine method of data classification, which has become an internationally validated reference textbook method of machine learning which is currently used in drug and diagnostic biomarker discovery world-wide.

RAMANANDA K. MADYASTHA, M.D., PH.D. Dr. Madyastha is the Recipient of the Raja Ravi Sher Singh of Kalsia Memorial Cancer Research Prize for outstanding contributions in the field of cancer research. He served on the Faculty of the Basic and Clinical Immunology and Microbiology Department at the Medical University of South Carolina. Dr. Madyastha has been an active member of the American Association of Cancer Research for more than 20 years. In addition, he is Board Certified by the American Board of Managed Care Medicine and is a licensed Clinical Laboratory Director. Dr. Madyastha was involved in the development of the first neural network based diagnostic tests for prostate and ovarian cancer.

KARY MULLIS, PH.D. Dr. Mullis was the recipient of the 1993 Nobel Prize in Chemistry for his invention of polymerase chain reaction (PCR) hailed as one of the greatest scientific accomplishments of the twentieth century, one that revolutionized genetic science and engineering. PCR was a commercial success, with the original patent being sold to Hoffman LaRoche for $300 million, generating hundreds of millions of dollars in revenues from royalties. In addition, Dr. Mullis was awarded the Japan Prize, one of international sciences most prestigious awards, the Thomas A. Edison Award, California Scientist of the Year Award, The National Biotechnology Award, The Gairdner Award in Toronto, Canada, the R&D Scientist of the Year Award, the William Allan Memorial Award of the American Society of Human Genetics and the Preis Biochemische Analytik of the German Society of Clinical Chemistry and Boehringer Mannheim. Dr. Mullis was inducted into the National Inventors Hall of Fame in 1998.

BERNHARD SCHOLKOPF, PH.D. Dr. Scholkopf is a director at the Max Plank Institute for Biological Cybernetics in Tubingen, Germany and an elected member of the Max Plank Society. Dr. Scholkopf was recently appointed Honorary Professor for machine learning at the Technical University in Berlin and has taught at the Humboldt University in Berlin. Dr. Scholkopf won the Prize for Best Scientific Project at the German National Research Center for Computer Science and his thesis on Support Vector Machines won the annual dissertation prize of the German Association for Computer Science. In addition, he is a former research scientist at AT&T Bell Labs, GMD-FIRST in Germany, the Australian National University, and Microsoft Research in the United Kingdom.

TIN-CHUEN YEUNG, PH.D., MBA Dr. Yeung is a pharmacologist, MBA and currently the head of Strategic Development, Life Sciences for the Chicago Law Firm, Bell, Boyd & Lloyd, LLC. He is admitted to practice patent law before the U.S. Patent Bar. At Bell, Boyd, and Lloyd, LLC he is a member of the intellectual property group responsible for patent prosecution in the areas of biotechnology, nanotechnology, pharmaceuticals, drug delivery technologies, medical devices

15

and other life sciences. Prior to his current position, Dr. Yeung served as President of Everest International, Inc. consultant to Fortune 500 medical technology companies and start-up biotechnology companies. He also served as Director of Strategy and Business Development for the Biosciences Division at Baxter International, Inc, where he managed the strategic development for world-wide development, marketing and manufacturing of recombinant protein products, as well as serving as Director of Corporate Development for Baxter, responsible for management of Baxter's acquisitions, technology development, licensing and strategic alliances. Dr. Yeung was formerly a research fellow at Harvard Medical School, Department of Pharmacology, studying the action and toxicity of anti-cancer drugs.

ITEM 10. EXECUTIVE COMPENSATION.

We do not have any revenue producing operations at the present time, and it may be some period of time before revenues are produced in amounts sufficient to pay executive salaries. When we have sufficient revenues we intend fix compensation levels for our executive officers at appropriate amounts.
During the fiscal year 2003 we granted to our President, David Cooper, and our Director of Corporate Development, Joe Fanelli immediately exercisable options to purchase our common stock. In each case the options are for 600,000 shares. Mr. Cooper and Mr. Fanelli both have the right to earn additional option grants upon the occurrence of specified conditions.

ITEM 11. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT.

The following table sets forth information concerning the beneficial ownership of our common stock as of February 27, 2004 by (i) each of our directors, and
(ii) all of our officers and directors as a group. Other than Dr. Barnhill, Mr. Braswell and Mr. Shaw no person is known to us to own shares of our common stock with 5% or more of the voting power of our company.

At February 27, 2004, there were 67,576,128 shares outstanding

                                    NUMBER OF SHARES
NAME AND POSITION                   BENEFICIALLY OWNED                 PERCENT OF CLASS (1)
-----------------                   ------------------                 --------------------

Dr. Stephen D. Barnhill             29,825,564 Indirect(2)                      44.00%
Chairman of the Board,
Chief Executive Officer and Medical Director
2 Springfield Place
Savannah, GA 37411


David Cooper, M.D., Ph.D.           600,000 Direct(3)                           0.009%
President
Chief Medical Officer Director
5842 Tree Line Drive
Fitchberg, Wisconsin 53711


                                       16

Robert S. Braswell IV               2,602,153 Direct (4)                        3.84%
Chief Administrative Officer          780,000 Indirect (5)                      1.15%r
Director, Secretary and Treasurer
One Chaparral Place
Lorena, TX 76655

Sandy Shaw                          3,825,000 Direct                            5.64%
Vice President and Director of Fractal Technology
111 Commonwealth Avenue
San Francisco, CA 94118

Joe Fanelli                         850,000 Direct (6)                          0.012%
Director of Corporate Development
8150 Harmony Grove Road
Escondido CA 92029

All officers and directors as       38,482,717                                  56.78%
a group ( five persons)


(1) Includes 600,000 options Granted to Dr. Cooper and 600,000 options granted to Mr. Fanelli, all of which are presently exercisable.
(2) These shares are held by Barnhill Group LLC which is wholly owned by Dr.
Barnhill
(3) These share are represented by presently exercisable options.
(4) Includes 11,667 shares are owned by Mr. Braswell and his wife as joint tenants.
(5) Includes 226, 676 shares are owned by Mr. Braswell's wife, 140,000 shares owned by a corporation controlled by Mr. Braswell and 413,324 shares owned by his minor children.
(6) These share are represented by presently exercisable options.

ITEM 12. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS.

On August 15, 2003, we entered into an agreement with Dr. Stephen Barnhill and the Barnhill Group LLC to purchase the assets of Barnhill Group LLC. As a part of the agreement the Barnhill Group LLC was to receive 29,825,564 shares of our common stock. The asset acquisition agreement was completed on September 24, 2003. The restricted shares of our common stock were issued to the Barnhill Group LLC on August 26, 2003. As a result of this transaction we acquired a 49% interest in Fractal Genomics. Dr. Barnhill currently serves as our Chief Executive Officer and the Chairman of our Board of Directors.

On August 29, 2003, we signed a binding letter of agreement to acquire all the assets of Fractal Genomics, a company founded and owned 51% by Mr. Sandy Shaw, in exchange for 3,825,000 shares of our common stock and a note for $500,000 payable quarterly in amounts of $62,500.

17

Our acquisition of the assets was completed on December 30, 2004. Mr. Shaw currently serves as a Director and as our Vice President, Fractal Technology.

18

ITEM 13. EXHIBITS AND REPORTS ON FORM 8-K.

(A) EXHIBITS.

3.1 Articles of Incorporation. Registrant incorporates by reference Exhibit

3.1 to Registration Statement on Form SB-2, File No. 333-62216, filed 6/04/2001.

3.1 (a) Articles of Amendment to Articles of Incorporation. Registrant incorporates by reference Exhibit 2.2 to Form10-QSB, File No. 333-62216, filed 11/14/2001.

3.1(b) Articles of Amendment to Articles of Incorporation changing Registrant name from Direct Wireless Communications, Inc., to Health Discovery Corporation.

3.2 By-Laws. Registrant incorporates by reference Exhibit 3.2 to Registration Statement on Form SB-2, File No. 333-62216, filed 6/04/2001.

4.1 Copy of Specimen Certificate for shares of common stock. Registrant incorporates by reference Exhibit 4.1 to Registration Statement on Form SB-2, File No. 333-62216, filed 6/04/2001.

4.1 (b) Copy of Specimen Certificate for shares of common stock.

4.2 Excerpt from By-Laws. Registrant incorporates by reference Exhibit 4.2 to Registration Statement on Form SB-2, File No. 333-62216, filed 6/04/2001.

4.2(A) Corrected Article 3.02 of By-Laws. Registrant incorporates by reference Exhibit 4.2(A) to Amendment No. 2 to Registration Statement on Form SB-2, File No. 333-62216, filed 8/15/2001

4.3(a) Non Qualified stock option agreements dated October 30, 2003 between registrant and David Cooper.

4.3(b) Non Qualified stock option agreements dated October 30,2003 between registrant and Joe Fanelli.

10.1(a) Technology License Agreement dated May 15, 2001, as amended July 17, 2001 between Direct Wireless Corporation and Direct Wireless Communications, Inc. Registrant incorporates by reference Exhibit 10.1(a) to Amendment No.1 to Registration Statement on Form SB-2, File No. 333-62216, filed 7/24/ 2001.

10.2 Asset purchase agreement between registrant dated September 15,2003 and Barnhill Group LLC.

10.3 Asset purchase agreement between registrant dated December 30,2003 and Fractal Genomics LLC.

23. Consent of Darilek Butler and CO, .P.C. Certified Public Accountant

31. Section 302 Certification of Robert S. Braswell IV

32. Certification of Robert S. Braswell IV

(B) REPORTS ON FORM 8-K. 8-K Filed September 12, 2003. Item 1 Change in Control of Registrant.

8-K Filed October 9, 2003 Item 2 Acquisition or Disposition of Assets.

19

HEALTH DISCOVERY CORPORATION
(FORMERLY KNOWN AS DIRECT WIRELESS COMMUNICATIONS, INC.)

FINANCIAL STATEMENTS
DECEMBER 31, 2003

TABLE OF CONTENTS

                                                               Page
                                                               ----

Independent Auditors' Report                                   F-2

Balance Sheet                                                  F-3

Statement of Loss                                              F-4

Statement of Changes in Stockholders' Equity                   F-5

Statement of Cash Flows                                        F-6

Notes to Financial Statements                                  F-7

F-1

DARILEK, BUTLER & CO., P.C.
2702 N. Loop 1604 E., Suite 202
San Antonio, Texas 78232
210-979-0055 phone
210-979-0058 fax

INDEPENDENT AUDITORS' REPORT

The Board of Directors
Health Discovery Corporation
(Formerly Known as Direct Wireless Communications, Inc.)
San Antonio, Texas

We have audited the accompanying balance sheet of Health Discovery Corporation (formerly known as Direct Wireless Communications, Inc.)(a Development Stage Company) as of December 31, 2003 and the related statements of income and cash flows for the period from inception (April 6, 2001) to December 31, 2003. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audit.

We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Health Discovery Corporation (formerly known as Direct Wireless Communications, Inc.) as of December 31, 2003 and the results of its operations and its cash flows for the initial period then ended in conformity with accounting principles generally accepted in the United States of America, consistently applied.

"Darilek, Butler & Co., P.C."

San Antonio, Texas
February 27, 2004

F-2

HEALTH DISCOVERY CORPORATION
(FORMERLY KNOWN AS DIRECT WIRELESS COMMUNICATIONS, INC.)
(A Development Stage Company)
Balance Sheet
December 31, 2003

                                                                                            2003
                                                                                       ---------------
ASSETS:

Current Assets
     Cash                                                                            $         76,589
                                                                                       --------------
          Total Current Assets                                                                 76,589
                                                                                       --------------

Other Assets
     Patent Costs                                                                                 510
     Accumulated Amortization                                                                     (14)
     Investment in The Barnhill Group, LLC                                                    596,511
     Investment in Fractal Genomics, LLC                                                      267,750
                                                                                       --------------
                                                                                              864,757
                                                                                       --------------
          Total Assets                                                               $        941,346
                                                                                       ==============

LIABILITIES AND STOCKHOLDERS' EQUITY:

Current Liabilities
     Accounts Payable - Trade                                                        $          5,587
     Accrued Liabilities                                                                        5,495
                                                                                       --------------
          Total Current Liabilities                                                            11,082
                                                                                       --------------
          Total Liabilities                                                                    11,082
                                                                                       --------------

Stockholders' Equity
    Common Stock, No Par Value, 200,000,000 Shares Authorized 66,576,128 Shares
         Issued and Outstanding                                                             1,822,023
    Additional Paid-In Capital                                                                216,719
    Deficit Accumulated During Development Stage                                           (1,108,478)
                                                                                       --------------
          Total Stockholders' Equity                                                          930,264
                                                                                       --------------
          Total Liabilities and Stockholders' Equity                                 $        941,346
                                                                                       ==============

The Accompanying Notes are an Integral Part of These Financial Statements.

F-3

HEALTH DISCOVERY CORPORATION
(FORMERLY KNOWN AS DIRECT WIRELESS COMMUNICATIONS, INC.)
(A Development Stage Company)
Statements of Loss
For the Year Ended December 31, 2003 and the Period from April 6, 2001 (Date of Inception) to December 31, 2003

                                                                               April 6, 2001
                                                             Year Ended        (Inception) to
                                                            December 31,        December 31,
                                                                2003                2003
                                                           ---------------     ---------------
Revenues
     Capital Gain (Loss) on Sale of Assets               $              0    $            (20)
     Dividend Income                                                    0                  64
     Miscellaneous Income                                              50                 326
                                                           ---------------     ---------------
Total Revenues                                                         50                 420
                                                           ---------------     ---------------

Expenses
     Administrative Fees                                           15,300              50,719
     Advertising                                                    4,498               7,568
     Amortization                                                      14                  14
     Auto Expense                                                       0                 272
     Bad Debt Expense                                               6,379               6,379
     Bank Charges                                                     289                 389
     Continuing Education                                             200                 200
     Dues and Subscriptions                                           604               1,404
     Equipment Lease                                                  244                 244
     Insurance                                                          0                 276
     Interest                                                           0                 118
     License Fees                                                  16,260             240,800
     Meals and Entertainment                                        1,211               1,551
     Office Expense                                                 3,476               8,366
     Other Expense                                                    387                 387
     Outside Services                                              76,625              80,841
     Postage and Delivery                                             828               2,893
     Professional and Consulting Fees                              57,270             641,597
     Rent Expense                                                     580               1,740
     Repairs and Maintenance                                          184                 239
     Salaries and Wages                                            26,667              26,667
     Stock Transaction Fees                                         2,396              10,481
     Supplies                                                          21               7,021
     Telephone                                                      2,080               2,080
     Travel                                                         3,726               5,561
                                                                   10,406              11,091
                                                           ---------------     ---------------
          Total Expenses                                          229,645           1,108,898
                                                           ---------------     ---------------
Net Loss Before Provision for Federal Income Tax                 (229,595)         (1,108,478)
Provision For Federal Income Tax                                        0                   0
                                                           ---------------     ---------------
Net Loss                                                 $       (229,595)   $     (1,108,478)
                                                           ===============     ===============


Average Outstanding Shares                                     33,776,646          19,809,111

Loss Per Share                                           $          (0.01)   $          (0.06)

The Accompanying Notes are an Integral Part of These Financial Statements.

F-4

HEALTH DISCOVERY CORPORATION
(FORMERLY KNOWN AS DIRECT WIRELESS COMMUNICATIONS, INC.)
Statement of Changes in Stockholders' Equity For the Period from April 6, 2001
(Date of Inception) to December 31, 2003

                                                                                                   Deficit
                                                                                                  Accumulated
                                                       Common Stock              Additional          During           Total
                                              --------------------------------     Paid-In        Development     Stockholders'
                                                 Shares             Amount         Capital           Stage            Equity
                                              --------------     -------------   -------------  ----------------  ---------------
Balance - April 6, 2001 (Inception)                       0    $            0  $            0 $               0 $              0
Contributed Services                                      0                 0          50,719                 0           50,719
Stock Issued for Cash                             5,469,150           298,493         166,000                 0          464,493
Stock Issued As Direct Wireless Corporation      10,138,975                 0               0                 0                0
Dividend
Stock Issued to Officers                          7,100,000                 0               0                 0                0
Stock Issued for Services                         6,342,439           589,746               0                 0          589,746
Stock Issued for Acquisitions                    33,650,564           864,261               0                 0          864,261
Stock Held In Escrow                              1,377,000                 0               0                 0                0
Cash Received for Sale of Escrowed Shares         2,498,000            69,523               0                 0           69,523
Net Loss                                                  0                 0               0        (1,108,478)      (1,108,478)
                                              --------------     -------------   -------------  ----------------  ---------------
Balance - December 31, 2003                      66,576,128    $    1,822,023  $      216,719 $      (1,108,478) $       930,264
                                              ==============     =============   =============  ================  ===============

The Accompanying Notes are an Integral Part of These Financial Statements.

F-5

HEALTH DISCOVERY CORPORATION
(FORMERLY KNOWN AS DIRECT WIRELESS COMMUNICATIONS, INC.)
(a Development Stage Company)
Statement of Cash Flows
From the Date of Inception (April 6, 2001) to December 31, 2003

Cash Flows From Operating Activities
         Net Loss                                                                   $      (1,108,478)
         Adjustments to Reconcile Net Loss to Net Cash
           Provided by (Used for) Operating Activities:
                   Services Contributed                                                        50,719
                   Services Provided for Stock                                                589,746
                   Patent Costs                                                                  (510)
                   Amortization                                                                    14
           Increase in:
                   Accounts Payable - Trade                                                     5,587
                   Accrued Liabilities                                                          5,495
                                                                                      ----------------
                  Net Cash Provided (Used) by Operating Activities                           (457,427)

Cash Flows From Investing Activities
         Sale (Purchase) of Mutual Funds                                                            0
                                                                                      ----------------
                   Net Cash Provided (Used) by Investing Activities                                 0

Cash Flows From Financing Activities
         Cash from Sale of Stock                                                              534,016
                                                                                      ---------------
                   Net Cash Provided (Used) by Financing Activities                           534,016

          Net Increase in Cash                                                                 76,589

Cash, at Beginning of Period                                                                        0
                                                                                      ----------------

Cash, at End of Period                                                              $          76,589
                                                                                      ================

Non-Cash Transactions:
----------------------

Services Contributed for Administration                             $ 50,719
                                                                    ========

Stock Issued for Professional and Consulting Services               $589,746
                                                                    ========

The Accompanying Notes are an Integral Part of These Financial Statements.

F-6

HEALTH DISCOVERY CORPORATION
(FORMERLY KNOWN AS DIRECT WIRELESS COMMUNICATIONS, INC.)
(a Development Stage Company)

Notes to Financial Statements
December 31, 2003

NOTE A - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NATURE OF OPERATIONS AND DESCRIPTION OF DEVELOPMENT STAGE ACTIVITIES

Health Discovery Corporation (formerly known as Direct Wireless Communications, Inc.) (the Company) has been in the development stage since the date of incorporation on April 6, 2001. The Company was primarily engaged in the activity of developing technology for a wireless telephone system. On May 15, 2001, the Company entered into a Technology Licensing Agreement with Direct Wireless Corporation (Direct Wireless). Under this agreement, the Company was granted a license to market and/or sublicense in the United States the wireless telephone communications technology on which Direct Wireless holds the patents. As described in Item 2 of the filing, the Company has recently acquired new technologies and has decided to abandon the telecommunications industry and compete in the biotechnology industry.

BASIS OF ACCOUNTING

The financial statements of the Company have been prepared on the accrual basis of accounting. As such, revenue is recognized as earned and expenses are recorded when accrued. This basis of accounting conforms to generally accepted accounting principles.

BASIS FOR ASSIGNING AMOUNTS TO EQUITY SECURITIES ISSUED FOR OTHER THAN CASH

Shares of common stock issued to individuals and/or companies for other than cash have been assigned amounts equal to the fair value of the service provided or the fair value of the shares of the Company issued, whichever was most readily determinable.

CASH FLOWS

For the purpose of the cash flow statement, cash and cash equivalents represent funds deposited in banks and investments maturing within three months.

USE OF ESTIMATES

Management uses estimates and assumptions in preparing financial statements. Those estimates and assumptions affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities, and the reported revenue and expenses. Actual results could differ from those estimates.

F-7

HEALTH DISCOVERY CORPORATION
(FORMERLY KNOWN AS DIRECT WIRELESS COMMUNICATIONS, INC.)
(a Development Stage Company)
Notes to Financial Statements
December 31, 2003

NOTE B - RELATED PARTY TRANSACTIONS

Direct Wireless Corporation provided office space and administrative services to the Company for the year until September 30, 2003. The estimated value for the services provided totaled $15,300 for the year ended December 31, 2003 and are recorded as administrative services in the accompanying financial statements.

NOTE C - LICENSE FEES EXPENSE - LICENSE AGREEMENT

Effective April 30, 2001, the Company entered into a license agreement with Direct Wireless Corporation. The Company had agreed to pay $10,000,000 under the terms of the license agreement to be paid as the Company gains money from the sale or sales of sub-licenses for the United States. The Company had also agreed to pay a percentage of all fees collected of licensed products to Direct Wireless under the terms of the agreement.

As a result of the Barnhill Group Acquisition, the license agreement was canceled.

The accompanying financial statements include $15,900 of license fees expensed that have been paid to Direct Wireless for the year ended December 31, 2003 and $240,440 from inception. No amortization of such fees have occurred during the development stage.

NOTE D - ESCROW AGREEMENT

The Company has established an irrevocable escrow agreement with a brokerage firm. The funds received from the sale of escrow shares were recorded as additional capital in the accompanying financial statements. As of December 31, 2003, the escrow agent has 1,377,000 shares remaining in the escrow fund.

NOTE E - FEDERAL INCOME TAXES

At December 31, 2003, the Company had net operating loss carryforwards totaling $1,108,478, which expire in 2023. Realization of deferred assets resulting from the NOL carryforwards have been offset by a valuation allowance.

F-8

EXHIBITS

INDEX TO EXHIBITS

3.1(b) Articles of Amendment to Articles of Incorporation changing Registrant name from Direct Wireless Communications, Inc., to Health Discovery Corporation.

4.1 (b) Copy of Specimen Certificate for shares of common stock.

4.3(a) Non Qualified stock option agreements dated October 30, 2003 between registrant and David Cooper.

4.3(b) Non Qualified stock option agreements dated October 30,2003 between registrant and Joe Fanelli.

10.2 Asset purchase agreement between registrant dated September 15,2003 and Barnhill Group LLC.

10.3 Asset purchase agreement between registrant dated December 30,2003 and Fractal Genomics LLC.

23. Consent of Darilek and Butler CO., PC.


SIGNATURES

In accordance with the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements of filing on Form SB-2 and authorized this registration statement to be signed on its behalf by the undersigned, in the City of Waco, State of Texas on September30, 2003.

Health Discovery Corporation

By: s/Stephen D. Barnhill M.D., Chief Executive Officer
    ---------------------------------------------------
 (Signatures and Title)

Stephen D. Barnhill M.D., Chief Executive Officer

In accordance with the requirements of the Securities Act of 1933, this registration statement was signed by the following persons in the capacities and on the dates stated:

Signature                                                         Date

/s/Stephen D. Barnhill M.D.                                       March 30, 2004
----------------------------------------------------
Stephen D. Barnhill M.D., Principal Executive Officer

/s/David Cooper                                                   March 30, 2004
-----------------------------------------------------
David Cooper, President and Medical director

/s/Robert S. Braswell IV                                          March 30, 2004
-----------------------------------------------------
Robert S. Braswell IV, Principal Financial Officer

/s/Robert S. Braswell, IV                                         March 30, 2004
--------------------------------------------
Robert S. Braswell, IV, Principal Accounting Officer

/s/Stephen D. Barnhill M.D.                                       March 30, 2004
-----------------------------------------------------
Stephen D. Barnhill M.D., Chairman of the Board

/s/Stephen D. Barnhill M.D.                                       March 30, 2004
-----------------------------------------------------
Stephen D. Barnhill M.D., Director

/s/Robert S. Braswell, IV                                         March 30, 2004
-----------------------------------------------------
Robert S. Braswell, IV, Director

/s/David Cooper                                                   March 30, 2004
-----------------------------------------------------
David Cooper, Director

S-1

EXHIBIT 3.1(b)

ARTICLES OF AMENDMENT
TO THE
ARTICLES OF INCORPORATION
OF
DIRECT WIRELESS COMMUNICATIONS, INC.

Pursuant to the provisions of Article 4.04 of the Texas Business Corporation Act, the undersigned corporation adopts the following articles of amendment to its Articles of Incorporation:

ARTICLE ONE

The name of the corporation is DIRECT WIRELESS COMMUNICATIONS, INC.

ARTICLE TWO

The following amendments to the Articles of Incorporation were adopted by the majority shareholders of the corporation on October 1, 2003, allowing the corporation to change its name.

ARTICLE THREE

The amendment alters and changes Article One. The numbering of the other Articles remains unchanged. The full text of such amended provisions are as follows:

ARTICLE I
NAME

The name of the corporation is Health Discovery Corporation

ARTICLE FOUR

The number of shares of the corporation outstanding at the time of such adoption was 59,751,128 and the number of shares entitled to vote thereon was 59,751,128

ARTICLE FIVE

The number of shares voted for such amendment was 41,541,567 by virtue of a consent of the majority of shareholders.

ARTICLE SIX

The amendment does not effect a change in the amount of stated capital

Dated October 15, 2003.

DIRECT WIRELESS COMMUNICATIONS, INC.

S: Bill G. Williams
BY: Bill G. Williams

Chief Executive Officer


EXHIBIT 4.1(b)


HEALTH DISCOVERY
CORPORATION

INCORPORATED UNDER THE LAWS OF THE STATE OF TEXAS
AUTHORIZED: 200,000,000 COMMON SHARES, NO PAR VALUE PER SHARE

THIS CERTIFIES THAT                                         SEE REVERSE FOR
                                                          CERTAIN DEFINITIONS
                                                        ------------------------
                                                           CUSIP 42218R 10 0
                                                        ------------------------
IS THE OWNER OF

FULLY PAID AND NON-ASSESSABLE COMMON STOCK, NO PAR VALUE OF

HEALTH DISCOVERY CORPORATION

transferable only on the books of this Corporation in person or by attorney upon surrender of this Certificate properly endorsed or assigned. This Certificate is not valid unless countersigned by the Transfer Agent and Registrar.

IN WITNESS WHEREOF, the said Corporation has caused this Certificate to be endorsed by the facsimile signatures of its duly authorized officers and to be sealed with the facsimile seal of the Corporation.

Dated:

[HEALTH DISCOVERY CORPORATION CORPORATE SEAL TEXAS]

Robert S. Braswell Stephen D. Barnhill
SECRETARY CHAIRMAN/CEO

COUNTERSIGNED:
CORPORATE STOCK TRANSFER, INC.
3200 Cherry Creek Drive, Suite 430, Denver, CO 80209

By: ________________________________________________ Transfer Agent and Registrar Authorized Officer


EXHIBIT 4.3(a)

NON-QUALIFIED STOCK OPTION AGREEMENT

THIS NON-QUALIFIED STOCK OPTION AGREEMENT (this "Agreement") is made on this 30th day of October, 2003 (the "Grant Date"), by and between DIRECT WIRELESS COMMUNICATIONS, INC., a Texas corporation (the "Company"), and DAVID COOPER, a Georgia resident (the "Optionee").

RECITALS:

WHEREAS, the Company desires to grant to Optionee an option to purchase shares of the Company's no par value common stock ("Common Stock"), and Optionee desires to accept such grant;

NOW, THEREFORE, the parties hereto, intending to be legally bound, agree as follows:

1. Grant of Option. The Board of Directors hereby grants Optionee an option to purchase from the Company a total of six hundred thousand (600,000) shares of Common Stock, at the purchase price of $0.01 per share (the "Purchase Price"), in accordance with the terms and conditions stated in this Agreement. The shares of Common Stock subject to the option granted hereby are referred to below as the "Shares," and the option to purchase such Shares is referred to below as the "Option." The Option is not intended to qualify as an "incentive stock option" within the meaning of Section 422 of the Internal Revenue Code of 1986.

2. Vesting of Option. The Option shall vest and become exercisable on the Grant Date. The Option may be exercised at any time and from time to time to purchase up to the number of Shares as to which it is then vested and exercisable at any subsequent date prior to termination of the Option.

3. Termination of Option. The Option shall remain exercisable until the earliest to occur of the dates specified below, upon which date the Option shall terminate:

(a) The date all of the Shares are purchased pursuant to the terms of this Agreement;

(b) At 5:00 P.M., Eastern Standard Time, on the date Optionee ceases to: (i) serve as an employee of the Company; and (ii) serve as a member of the Company's Board of Directors (a "Termination of Relationship") for Cause (as defined below);

(c) At 5:00 P.M., Eastern Standard Time, on the ninetieth (90th) day following a Termination of Relationship for any reason other than Cause;


(d) At 5:00 P.M., Eastern Standard Time, on the last date specified in the notice described below in the event of a Corporate Reorganization (as defined below), except to the extent that the Option is assumed by the surviving entity or affiliate thereof in connection with such Corporate Reorganization (provided that in the event of a Corporate Reorganization, the Company shall send Optionee prior written notice of the effectiveness of such event and the last day on which Optionee may exercise the Option); or

(e) At 5:00 P.M., Eastern Standard Time, on the tenth (10th) anniversary of the Grant Date.

Upon its termination, the Option shall have no further force or effect and Optionee shall have no further rights under the Option or to any Shares that have not been purchased pursuant to prior exercise of the Option.

As used in this Section 3, "Cause" means any of the following: (i) the conviction of Optionee of any felony or any crime or act of dishonesty, fraud or moral turpitude; (ii) the judicial determination of Optionee as civilly liable for any act of fraud, gross negligence or tortious misconduct involving the Company; (iii) any act or omission by Optionee which constitutes a material breach by Optionee of his obligations under any present or future written agreement of employment between Optionee and the Company (which has not been cured within 30 days after written notice of such failure from the Company to Optionee); (iv) use of illegal drugs, drunkenness or other substance abuse by Optionee; (v) insubordination, gross incompetence or willful misconduct by Optionee in the performance of his duties under any present or future written agreement of employment between Optionee and the Company; (vi) excessive absenteeism (more than 10 days during any twelve-month period) by Optionee not related to illnesses, sick leave or authorized vacations; or (vii) any other act or omission by Optionee (other than an act or omission resulting from the exercise by Optionee of good faith business judgment) which materially impairs the financial condition or business reputation of the Company or is otherwise materially detrimental to the Company. Any determination as to whether a Termination of Relationship has occurred shall be made by the Board of Directors in its good faith discretion

For purposes of this Agreement, a "Corporate Reorganization" shall mean any of the following events: (a) any person (as such term is defined in Section 13(d) of the Securities Exchange Act of 1934 (the "Exchange Act")), group, corporation or other entity (other than the Company or any subsidiary of the Company), purchases shares pursuant to a tender offer or exchange offer to acquire any Common Stock of the Company for cash, securities or any other consideration, provided that after consummation of the offer, the person, group, corporation or other entity in question is the beneficial owner (as such term is defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of fifty percent (50%) or more of the outstanding Common Stock of the Company; or (b) the shareholders of the Company approve (i) any consolidation or merger of the Company in which the Company is not the continuing or surviving corporation or pursuant to which shares of Common Stock would be converted into cash, securities or other property, or (ii) any sale, lease, exchange or other transfer (in one transaction or a series of related transactions) of all or substantially all of the assets of the Company


4. Exercise of Option.

(a) The Option may be exercised only by (i) Optionee's completion, execution and delivery to the Company of a notice of exercise and, if required by the Company, a subscription agreement as supplied by the Company, and (ii) the payment to the Company, pursuant to the terms of this Agreement, of an amount equal to the Purchase Price multiplied by the number of Shares being purchased as specified in Optionee's notice of exercise (which Purchase Price may be paid to the Company in cash or by Optionee's execution and delivery to the Company of a promissory note mutually acceptable to the Company and the Optionee). Optionee must provide notice of exercise of the Option with respect to no fewer than 100 Shares (or any lesser number of Shares with respect to which the Option is vested and exercisable). Notwithstanding anything to the contrary in this Agreement, the Option may be exercised only if compliance with all applicable federal and state securities laws can be effected.

(b) Upon any exercise of the Option by Optionee or as soon thereafter as is practicable, the Company shall issue and deliver to Optionee a certificate or certificates evidencing such number of Shares as Optionee has then elected to purchase. Such certificate or certificates shall be registered in the name of Optionee and shall bear any legend required by any federal or state securities laws.

5. Shares Reserved. The Company shall at all times from and after the Grant Date reserve and keep available out of its authorized and unissued Common Stock, solely for the purpose of providing for the exercise of the rights to purchase all Shares granted pursuant to this Option, such number of shares of Common Stock as shall, from time to time, be sufficient therefor. The Company covenants that all shares of Common Stock issuable upon exercise of this Option, upon receipt by the Company of the full Purchase Price therefor, shall be validly issued, fully paid and nonassessable.

6. Certain Adjustments.

(a) In case the Company shall at any time after the Grant Date
(i) declare a dividend on the outstanding Common Stock payable in shares of its capital stock, (ii) subdivide the outstanding Common Stock, (iii) combine the outstanding Common Stock into a smaller number of shares, or (iv) issue any shares of its capital stock by reclassification of the Common Stock (including any such reclassification in connection with a consolidation or merger in which the Company is the continuing corporation), then, in each case, the Purchase Price, and the number of Shares issuable upon exercise of this Option, in effect at the time of the record date for such dividend or of the effective date of such subdivision, combination, or reclassification, shall be proportionately adjusted so that the Optionee after such time shall be entitled to receive the aggregate number and kind of shares which, if such Option had been exercised immediately prior to such time, he would have owned upon such exercise and been entitled to receive by virtue of such dividend, subdivision, combination, or reclassification. Such adjustment shall be made successively whenever any event listed above shall occur.


(b) Whenever there shall be an adjustment as provided in this
Section 6, the Company shall promptly cause written notice thereof to be sent to the Optionee, which notice shall be accompanied by an officer's certificate setting forth the number of Shares purchasable upon the exercise of this Option and the Purchase Price after such adjustment and setting forth a brief statement of the facts requiring such adjustment and the computation thereof, which officer's certificate shall be conclusive evidence of the correctness of any such adjustment absent manifest error.

(c) The Company shall not be required to issue fractions of shares of Common Stock or other capital stock of the Company upon the exercise of this Option. If any fraction of a share would be issuable on the exercise of this Option, the Company shall purchase such fraction for an amount in cash equal to the same fraction of the Purchase Price on the date of exercise of this Option.

7. Adjustments for Corporate Reorganization. If this Option is assumed by the surviving entity or affiliate thereof in any Corporate Reorganization, and such Corporate Reorganization is effected in such a way that holders of Common Stock shall be entitled to receive stock, securities, cash or assets with respect to or in exchange for Common Stock, then, as a condition of such Corporate Reorganization, appropriate provision shall be made whereby the holder of this Option shall thereafter have the right to purchase and receive upon the basis and upon the terms and conditions specified in this Option, upon exercise this Option and in lieu of the Shares immediately theretofore purchasable and receivable upon the exercise of the rights represented hereby, such number, amount and like kind of shares of stock, securities, cash or assets as may be issued or payable pursuant to the terms of the Corporate Reorganization with respect to or in exchange for the number of shares of Common Stock immediately theretofore purchasable and receivable upon the exercise of the rights represented hereby as if such shares were outstanding immediately prior to the Corporate Reorganization, and in any such case appropriate provision shall be made with respect to the rights and interest of the holders (including, without limitation, provisions for adjustments of the Purchase Price and of the number of Shares purchasable and receivable upon the exercise of this Option) to the end that the provisions hereof shall thereafter be applicable, as nearly as may be practicable, in relation to any shares of stock or securities thereafter deliverable upon the exercise hereof.

8. Rights Prior to Exercise. Optionee will have no rights as a shareholder with respect to the Shares except to the extent that Optionee has exercised the Option and has been issued and received delivery of a certificate or certificates evidencing the Shares so purchased.

9. Relationship with Optionee. Nothing in this Agreement shall be construed as constituting a commitment, guarantee, agreement or understanding of any kind or nature that the Company shall employ or engage Optionee, nor shall this Agreement affect in any way the right of the Company to terminate the relationship between the Company and the Optionee at any time and for any reason.


10. Lock-Up. Optionee hereby agrees that he shall not, without the consent of the managing underwriter, sell, transfer, pledge, hypothecate or otherwise transfer or dispose of any Common Stock or other shares of stock of the Company then owned by Optionee for up to 180 days following the effective date of a registration statement (other than a registration statement relating to any employee benefit plan, or with respect to a corporate reorganization or other transaction under Rule 145 promulgated under the Securities Act of 1933) of the Company for a public offering. In order to enforce the foregoing covenant, the Company shall have the right to place restrictive legends on the certificates representing the shares subject to this Section and to impose stop transfer instructions with respect to the Common Stock.

11. Restrictions on Transferability. The Option shall not be transferable by Optionee otherwise than by will or by the laws of descent and distribution, and shall be exercisable during Optionee's lifetime only by Optionee.

12. Further Restrictions on Exercise and Sale. Optionee acknowledges and understands that the Shares subject to this Option is not registered under the Securities Act of 1933 or under applicable state securities laws. The Option shall be subject to the requirement that if at any time the Board of Directors shall determine, in its discretion, that the listing, registration or qualification of the Shares subject to such Option upon any securities exchange or under any state or federal law, or the consent or approval of any government regulatory body, is necessary or desirable as a condition of, or in connection with, the granting of such Option or the exercise thereof, such Option may not be exercised in whole or in part unless such listing, registration, qualification, consent or approval shall have been effected or obtained free of any conditions not acceptable to the Board of Directors. The costs of any such listing, registration, qualification, consent or approval shall be paid by the Company. Alternatively, the Company shall not permit any exercise of this Option unless it receives such representations, factual assurances, and legal opinions as it may deem necessary to determine and document the availability of an exemption from registration under federal and state securities laws with respect to any particular issuance of shares under this Agreement. Further, the Board of Directors shall require that Shares issued in respect of any exercise of this Option shall bear such restrictions on further transfer as shall be necessary to insure the availability of any exemption so claimed.

13. General Provisions.

(a) This Agreement shall be construed and enforced in accordance with and governed by the laws of the State of Texas.

(b) This Agreement represents the entire agreement between the parties with respect to the subject matter hereof and may be modified or amended only in a writing signed by all parties hereto.

(c) The rights and obligations of the Company and Optionee hereunder shall be binding upon, inure to the benefit of and be enforceable against their respective successors and assigns, legal representatives and heirs. The rights of Optionee hereunder may be assigned only with the prior written consent of the Company.


(d) Either party's failure to enforce any provision or provisions of this Agreement shall not in any way be construed as a waiver of any such provision or provisions, nor prevent the party thereafter from enforcing each and every other provision of this Agreement. The rights granted the parties herein are cumulative and shall not constitute a waiver of any party's right to assert all other legal remedies available to it under the circumstances.

(e) The Company and Optionee agree, upon request, to execute any further documents or instruments necessary or desirable to carry out the purposes or intent of this Agreement.

[Signatures appear on following page]


IN WITNESS WHEREOF, the Company and Optionee have executed this Agreement as of the date first above written.

COMPANY:

DIRECT WIRELESS COMMUNICATIONS, INC.

By: /s/ Stephen D. Barnhill
    -----------------------
Title: Chairman and C.E.O.

OPTIONEE:

/s/ David Cooper
----------------
David Cooper


NON-QUALIFIED STOCK OPTION AGREEMENT

THIS NON-QUALIFIED STOCK OPTION AGREEMENT (this "Agreement") is made on this 30th day of October, 2003 (the "Grant Date"), by and between DIRECT WIRELESS COMMUNICATIONS, INC., a Texas corporation (the "Company"), and DAVID COOPER, a Georgia resident (the "Optionee").

RECITALS:

WHEREAS, the Company desires to grant to Optionee an option to purchase shares of the Company's no par value common stock ("Common Stock"), and Optionee desires to accept such grant;

NOW, THEREFORE, the parties hereto, intending to be legally bound, agree as follows:

14. Grant of Option. The Board of Directors hereby grants Optionee an option to purchase from the Company a total of two million four hundred thousand (2,400,000) shares of Common Stock, at the purchase price of $0.10 per share (the "Purchase Price"), in accordance with the terms and conditions stated in this Agreement. The shares of Common Stock subject to the option granted hereby are referred to below as the "Shares," and the option to purchase such Shares is referred to below as the "Option." The Option is not intended to qualify as an "incentive stock option" within the meaning of Section 422 of the Internal Revenue Code of 1986.

15. Vesting of Option.

(a) The Option shall vest and become exercisable as follows:

(i) four hundred thousand (400,000) shares shall vest on November 1, 2004;

(ii) four hundred thousand (400,000) shares shall vest on November 1, 2005;

(iii) four hundred thousand (400,000) shares shall vest on November 1, 2006;

(iv) four hundred thousand (400,000) shares shall vest at such time as the Company has, through Optionee's efforts: (a) raised a minimum of $1,000,000 (whether via the sale of equity securities, the generation of revenue, the receipt of government grants or otherwise, but specifically excluding via the borrowing of money ("Qualified Funding")) and (b) entered into two customer contracts, at least one of which is revenue-generating;


(v) four hundred thousand (400,000) shares shall vest at such time as the Company has, through Optionee's efforts: (a) raised an additional $1,000,000 of Qualified Funding and (b) executed two additional customer contracts, at least one of which is revenue-generating; and

(vi) four hundred thousand (400,000) shares shall vest at such time as the Company has, through Optionee's efforts: (a) raised an additional $1,000,000 of Qualified Funding and (b) executed two additional customer contracts, at least one of which is revenue-generating.

The Company shall, in its sole good faith discretion, determine whether the milestones set forth in subsections (iv), (v) and (vi) have been satisfied, and any such determination by the Company shall be final and binding on the parties.

(b) Notwithstanding the foregoing, in the event of a Corporate Reorganization, the Option shall become vested and exercisable in its entirety concurrent with the closing of such Corporate Reorganization. For purposes of this Agreement, a "Corporate Reorganization" shall mean any of the following events: (a) any person (as such term is defined in Section 13(d) of the Securities Exchange Act of 1934 (the "Exchange Act")), group, corporation or other entity (other than the Company or any subsidiary of the Company), purchases shares pursuant to a tender offer or exchange offer to acquire any Common Stock of the Company for cash, securities or any other consideration, provided that after consummation of the offer, the person, group, corporation or other entity in question is the beneficial owner (as such term is defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of fifty percent (50%) or more of the outstanding Common Stock of the Company; or (b) the shareholders of the Company approve (i) any consolidation or merger of the Company in which the Company is not the continuing or surviving corporation or pursuant to which shares of Common Stock would be converted into cash, securities or other property, or (ii) any sale, lease, exchange or other transfer (in one transaction or a series of related transactions) of all or substantially all of the assets of the Company.

(c) Vesting is cumulative, so that Shares as to which the Option has become vested and exercisable may be purchased pursuant to exercise of the Option at any subsequent date prior to termination of the Option. The Option may be exercised at any time and from time to time to purchase up to the number of Shares as to which it is then vested and exercisable.

16. Forfeiture Upon Termination of Engagement. If Optionee ceases to:
(i) serve as an employee of the Company; and (ii) serve as a member of the Company's Board of Directors (a "Termination of Relationship"), any portion of the Option that is not then vested shall be terminated and immediately forfeited, and Optionee shall have no rights in such portion of the Option. Any determination as to whether a Termination of Relationship has occurred shall be made by the Board of Directors in its good faith discretion.


17. Termination of Option. Subject to Sections 2 and 3 above, the Option shall remain exercisable until the earliest to occur of the dates specified below, upon which date the Option shall terminate:

(a) The date all of the Shares are purchased pursuant to the terms of this Agreement;

(b) At 5:00 P.M., Eastern Standard Time, on the date of Termination of Relationship for Cause (as defined below);

(c) At 5:00 P.M., Eastern Standard Time, on the ninetieth (90th) day following a Termination of Relationship for any reason other than Cause;

(d) At 5:00 P.M., Eastern Standard Time, on the last date specified in the notice described below in the event of a Corporate Reorganization, except to the extent that the Option is assumed by the surviving entity or affiliate thereof in connection with such Corporate Reorganization (provided that in the event of a Corporate Reorganization, the Company shall send Optionee prior written notice of the effectiveness of such event and the last day on which Optionee may exercise the Option); or

(e) At 5:00 P.M., Eastern Standard Time, on the tenth anniversary of the Grant Date.

Upon its termination, the Option shall have no further force or effect and Optionee shall have no further rights under the Option or to any Shares that have not been purchased pursuant to prior exercise of the Option.

As used in this Section 4, "Cause" means any of the following: (i) the conviction of Optionee of any felony or any crime or act of dishonesty, fraud or moral turpitude, (ii) the judicial determination of Optionee as civilly liable for any act of fraud, gross negligence or tortious misconduct involving the Company, (iii) any act or omission by Optionee which constitutes a material breach by Optionee of his obligations under any present or future written agreement of employment between Optionee and the Company (which has not been cured within 30 days after written notice of such failure from the Company to Optionee), (iv) use of illegal drugs, drunkenness or other substance abuse by Optionee, (v) insubordination, gross incompetence or willful misconduct by Optionee in the performance of his duties under any present or future written agreement of employment between Optionee and the Company, (vi) excessive absenteeism (more than 10 days during any twelve-month period) by Optionee not related to illnesses, sick leave or authorized vacations, or (vii) any other act or omission by Optionee (other than an act or omission resulting from the exercise by Optionee of good faith business judgment) which materially impairs the financial condition or business reputation of the Company or is otherwise materially detrimental to the Company.

18. Exercise of Option.

(a) The Option may be exercised only by (i) Optionee's completion, execution and delivery to the Company of a notice of exercise and, if required by the


Company, a subscription agreement as supplied by the Company, and (ii) the payment to the Company, pursuant to the terms of this Agreement, of an amount equal to the Purchase Price multiplied by the number of Shares being purchased as specified in Optionee's notice of exercise (which Purchase Price may be paid to the Company in cash or by Optionee's execution and delivery to the Company of a promissory note mutually acceptable to the Company and the Optionee). Optionee must provide notice of exercise of the Option with respect to no fewer than 100 Shares (or any lesser number of Shares with respect to which the Option is vested and exercisable). Notwithstanding anything to the contrary in this Agreement, the Option may be exercised only if compliance with all applicable federal and state securities laws can be effected.

(b) Upon any exercise of the Option by Optionee or as soon thereafter as is practicable, the Company shall issue and deliver to Optionee a certificate or certificates evidencing such number of Shares as Optionee has then elected to purchase. Such certificate or certificates shall be registered in the name of Optionee and shall bear any legend required by any federal or state securities laws.

19. Shares Reserved. The Company shall at all times from and after the Grant Date reserve and keep available out of its authorized and unissued Common Stock, solely for the purpose of providing for the exercise of the rights to purchase all Shares granted pursuant to this Option, such number of shares of Common Stock as shall, from time to time, be sufficient therefor. The Company covenants that all shares of Common Stock issuable upon exercise of this Option, upon receipt by the Company of the full Purchase Price therefor, shall be validly issued, fully paid and nonassessable.

20. Certain Adjustments.

(a) In case the Company shall at any time after the Grant Date
(i) declare a dividend on the outstanding Common Stock payable in shares of its capital stock, (ii) subdivide the outstanding Common Stock, (iii) combine the outstanding Common Stock into a smaller number of shares, or (iv) issue any shares of its capital stock by reclassification of the Common Stock (including any such reclassification in connection with a consolidation or merger in which the Company is the continuing corporation), then, in each case, the Purchase Price, and the number of Shares issuable upon exercise of this Option, in effect at the time of the record date for such dividend or of the effective date of such subdivision, combination, or reclassification, shall be proportionately adjusted so that the Optionee after such time shall be entitled to receive the aggregate number and kind of shares which, if such Option had been exercised immediately prior to such time, he would have owned upon such exercise and been entitled to receive by virtue of such dividend, subdivision, combination, or reclassification. Such adjustment shall be made successively whenever any event listed above shall occur.

(b) Whenever there shall be an adjustment as provided in this
Section 7, the Company shall promptly cause written notice thereof to be sent to the Optionee, which notice shall be accompanied by an officer's certificate setting forth the number of Shares purchasable upon the exercise of this Option and the Purchase Price after such adjustment


and setting forth a brief statement of the facts requiring such adjustment and the computation thereof, which officer's certificate shall be conclusive evidence of the correctness of any such adjustment absent manifest error.

(c) The Company shall not be required to issue fractions of shares of Common Stock or other capital stock of the Company upon the exercise of this Option. If any fraction of a share would be issuable on the exercise of this Option, the Company shall purchase such fraction for an amount in cash equal to the same fraction of the Purchase Price on the date of exercise of this Option.

21. Adjustments for Corporate Reorganization. If this Option is assumed by the surviving entity or affiliate thereof in any Corporate Reorganization, and such Corporate Reorganization is effected in such a way that holders of Common Stock shall be entitled to receive stock, securities, cash or assets with respect to or in exchange for Common Stock, then, as a condition of such Corporate Reorganization, appropriate provision shall be made whereby the holder of this Option shall thereafter have the right to purchase and receive upon the basis and upon the terms and conditions specified in this Option, upon exercise this Option and in lieu of the Shares immediately theretofore purchasable and receivable upon the exercise of the rights represented hereby, such number, amount and like kind of shares of stock, securities, cash or assets as may be issued or payable pursuant to the terms of the Corporate Reorganization with respect to or in exchange for the number of shares of Common Stock immediately theretofore purchasable and receivable upon the exercise of the rights represented hereby as if such shares were outstanding immediately prior to the Corporate Reorganization, and in any such case appropriate provision shall be made with respect to the rights and interest of the holders (including, without limitation, provisions for adjustments of the Purchase Price and of the number of Shares purchasable and receivable upon the exercise of this Option) to the end that the provisions hereof shall thereafter be applicable, as nearly as may be practicable, in relation to any shares of stock or securities thereafter deliverable upon the exercise hereof.

22. Rights Prior to Exercise. Optionee will have no rights as a shareholder with respect to the Shares except to the extent that Optionee has exercised the Option and has been issued and received delivery of a certificate or certificates evidencing the Shares so purchased.

23. Relationship with Optionee. Nothing in this Agreement shall be construed as constituting a commitment, guarantee, agreement or understanding of any kind or nature that the Company shall employ or engage Optionee, nor shall this Agreement affect in any way the right of the Company to terminate the relationship between the Company and the Optionee at any time and for any reason.

24. Lock-Up. Optionee hereby agrees that he shall not, without the consent of the managing underwriter, sell, transfer, pledge, hypothecate or otherwise transfer or dispose of any Common Stock or other shares of stock of the Company then owned by Optionee for up to 180 days following the effective date of a registration statement (other than a registration statement relating to any employee benefit plan, or with respect to a corporate


reorganization or other transaction under Rule 145 promulgated under the Securities Act of 1933) of the Company for a public offering. In order to enforce the foregoing covenant, the Company shall have the right to place restrictive legends on the certificates representing the shares subject to this
Section and to impose stop transfer instructions with respect to the Common Stock.

25. Restrictions on Transferability. The Option shall not be transferable by Optionee otherwise than by will or by the laws of descent and distribution, and shall be exercisable during Optionee's lifetime only by Optionee.

26. Further Restrictions on Exercise and Sale. Optionee acknowledges and understands that the Shares subject to this Option is not registered under the Securities Act of 1933 or under applicable state securities laws. The Option shall be subject to the requirement that if at any time the Board of Directors shall determine, in its discretion, that the listing, registration or qualification of the Shares subject to such Option upon any securities exchange or under any state or federal law, or the consent or approval of any government regulatory body, is necessary or desirable as a condition of, or in connection with, the granting of such Option or the exercise thereof, such Option may not be exercised in whole or in part unless such listing, registration, qualification, consent or approval shall have been effected or obtained free of any conditions not acceptable to the Board of Directors. The costs of any such listing, registration, qualification, consent or approval shall be paid by the Company. Alternatively, the Company shall not permit any exercise of this Option unless it receives such representations, factual assurances, and legal opinions as it may deem necessary to determine and document the availability of an exemption from registration under federal and state securities laws with respect to any particular issuance of shares under this Agreement. Further, the Board of Directors shall require that Shares issued in respect of any exercise of this Option shall bear such restrictions on further transfer as shall be necessary to insure the availability of any exemption so claimed.

27. General Provisions.

(a) This Agreement shall be construed and enforced in accordance with and governed by the laws of the State of Texas.

(b) This Agreement represents the entire agreement between the parties with respect to the subject matter hereof and may be modified or amended only in a writing signed by all parties hereto.

(c) The rights and obligations of the Company and Optionee hereunder shall be binding upon, inure to the benefit of and be enforceable against their respective successors and assigns, legal representatives and heirs. The rights of Optionee hereunder may be assigned only with the prior written consent of the Company.

(d) Either party's failure to enforce any provision or provisions of this Agreement shall not in any way be construed as a waiver of any such provision or provisions, nor prevent the party thereafter from enforcing each and every other provision of this Agreement. The rights granted the parties herein are cumulative and shall not constitute a waiver of any party's right to assert all other legal remedies available to it under the circumstances.


(e) The Company and Optionee agree, upon request, to execute any further documents or instruments necessary or desirable to carry out the purposes or intent of this Agreement.

[Signatures appear on following page]


IN WITNESS WHEREOF, the Company and Optionee have executed this Agreement as of the date first above written.

COMPANY:

DIRECT WIRELESS COMMUNICATIONS, INC.

By: /s/ Stephen D. Barnhill
    -----------------------
Title: Chairman and C.E.O.

OPTIONEE:

/s/ David Cooper
----------------
David Cooper


EXHIBIT 4.3(b)

AMENDED AND RESTATED
NON-QUALIFIED STOCK OPTION AGREEMENT

THIS AMENDED AND RESTATED NON-QUALIFIED STOCK OPTION AGREEMENT (this "Agreement") is made on this 1st day of December, 2003 (the "Grant Date"), by and between HEALTH DISCOVERY CORPORATION, a Texas corporation (the "Company"), and JOE FANELLI, a California resident (the "Optionee").

RECITALS:

WHEREAS, the Company granted Optionee an option to purchase shares of the Company's no par value common stock ("Common Stock") pursuant to a Non-Qualified Stock Option Agreement dated October 30, 2003 (the "Original Agreement");

WHEREAS, the parties desire to amend and restate the Original Agreement;

NOW, THEREFORE, the parties hereto, intending to be legally bound, agree as follows:

28. Grant of Option. The Board of Directors hereby grants Optionee an option to purchase from the Company a total of one million nine hundred thousand (1,900,000) shares of Common Stock, at the purchase price of $0.10 per share (the "Purchase Price"), in accordance with the terms and conditions stated in this Agreement. The shares of Common Stock subject to the option granted hereby are referred to below as the "Shares," and the option to purchase such Shares is referred to below as the "Option." The Option is not intended to qualify as an "incentive stock option" within the meaning of Section 422 of the Internal Revenue Code of 1986.

29. Vesting of Option.

(a) The Option shall vest and become exercisable as follows:

(i) 400,004 shares shall vest on November 1, 2004;

(ii) 400,000 shares shall vest on November 1, 2005;

(iii) 400,000 shares shall vest on November 1, 2006;

(iv) 349,998 shares shall vest in increments of 58,333 shares apiece, each time the Company has, principally through Optionee's efforts, raised $500,000 (whether via the sale of equity securities, the generation of revenue, the receipt of government grants or otherwise, but specifically excluding via the borrowing of money); and

(v) 349,998 shares shall vest in increments of 58,333 shares apiece, each time the Company has, principally through Optionee's efforts,


executed a revenue-generating customer contract.

The Company shall, in its sole good faith discretion, determine whether the milestones set forth in subsections (iv) and (v) have been satisfied, and any such determination by the Company shall be final and binding on the parties.

(b) Notwithstanding the foregoing, in the event of a Corporate Reorganization, the Option shall become vested and exercisable in its entirety concurrent with the closing of such Corporate Reorganization. For purposes of this Agreement, a "Corporate Reorganization" shall mean any of the following events: (a) any person (as such term is defined in Section 13(d) of the Securities Exchange Act of 1934 (the "Exchange Act")), group, corporation or other entity (other than the Company or any subsidiary of the Company), purchases shares pursuant to a tender offer or exchange offer to acquire any Common Stock of the Company for cash, securities or any other consideration, provided that after consummation of the offer, the person, group, corporation or other entity in question is the beneficial owner (as such term is defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of fifty percent (50%) or more of the outstanding Common Stock of the Company; or (b) the shareholders of the Company approve (i) any consolidation or merger of the Company in which the Company is not the continuing or surviving corporation or pursuant to which shares of Common Stock would be converted into cash, securities or other property, or (ii) any sale, lease, exchange or other transfer (in one transaction or a series of related transactions) of all or substantially all of the assets of the Company.

(c) Vesting is cumulative, so that Shares as to which the Option has become vested and exercisable may be purchased pursuant to exercise of the Option at any subsequent date prior to termination of the Option. The Option may be exercised at any time and from time to time to purchase up to the number of Shares as to which it is then vested and exercisable.

30. Forfeiture Upon Termination of Engagement. If Optionee ceases to serve as an employee of the Company (a "Termination of Relationship"), any portion of the Option that is not then vested shall be terminated and immediately forfeited, and Optionee shall have no rights in such portion of the Option. Any determination as to whether a Termination of Relationship has occurred shall be made by the Board of Directors in its good faith discretion.

31. Termination of Option. Subject to Sections 2 and 3 above, the Option shall remain exercisable until the earliest to occur of the dates specified below, upon which date the Option shall terminate:

(a) The date all of the Shares are purchased pursuant to the terms of this Agreement;

(b) At 5:00 P.M., Eastern Standard Time, on the date of Termination of Relationship for Cause (as defined below);


(c) At 5:00 P.M., Eastern Standard Time, on the nine-month anniversary of a Termination of Relationship for any reason other than Cause;

(d) At 5:00 P.M., Eastern Standard Time, on the last date specified in the notice described below in the event of a Corporate Reorganization, except to the extent that the Option is assumed by the surviving entity or affiliate thereof in connection with such Corporate Reorganization (provided that in the event of a Corporate Reorganization, the Company shall send Optionee prior written notice of the effectiveness of such event and the last day on which Optionee may exercise the Option); or

(e) At 5:00 P.M., Eastern Standard Time, on the tenth anniversary of the Grant Date.

Upon its termination, the Option shall have no further force or effect and Optionee shall have no further rights under the Option or to any Shares that have not been purchased pursuant to prior exercise of the Option.

As used in this Section 4, "Cause" means any of the following: (i) the conviction of Optionee of any felony or any crime or act of dishonesty, fraud or moral turpitude, (ii) the judicial determination of Optionee as civilly liable for any act of fraud, gross negligence or tortious misconduct involving the Company, (iii) any act or omission by Optionee which constitutes a material breach by Optionee of his obligations under any present or future written agreement of employment between Optionee and the Company (which has not been cured within 30 days after written notice of such failure from the Company to Optionee), (iv) use of illegal drugs, drunkenness or other substance abuse by Optionee, (v) insubordination, gross incompetence or willful misconduct by Optionee in the performance of his duties under any present or future written agreement of employment between Optionee and the Company, (vi) at such time as Optionee is serving as a full-time employee of the Company, excessive absenteeism (more than 10 days during any twelve-month period) by Optionee not related to illnesses, sick leave or authorized vacations, or (vii) any other act or omission by Optionee (other than an act or omission resulting from the exercise by Optionee of good faith business judgment) which materially impairs the financial condition or business reputation of the Company or is otherwise materially detrimental to the Company.

32. Exercise of Option.

(a) The Option may be exercised only by (i) Optionee's completion, execution and delivery to the Company of a notice of exercise and, if required by the Company, a subscription agreement as supplied by the Company, and (ii) the payment to the Company, pursuant to the terms of this Agreement, of an amount equal to the Purchase Price multiplied by the number of Shares being purchased as specified in Optionee's notice of exercise (which Purchase Price may be paid to the Company in cash or by Optionee's execution and delivery to the Company of a promissory note mutually acceptable to the Company and the Optionee). Optionee must provide notice of exercise of the Option with respect to no fewer than 100 Shares (or any lesser number of Shares with respect to which


the Option is vested and exercisable). Notwithstanding anything to the contrary in this Agreement, the Option may be exercised only if compliance with all applicable federal and state securities laws can be effected.

(b) Upon any exercise of the Option by Optionee or as soon thereafter as is practicable, the Company shall issue and deliver to Optionee a certificate or certificates evidencing such number of Shares as Optionee has then elected to purchase. Such certificate or certificates shall be registered in the name of Optionee and shall bear any legend required by any federal or state securities laws.

33. Shares Reserved. The Company shall at all times from and after the Grant Date reserve and keep available out of its authorized and unissued Common Stock, solely for the purpose of providing for the exercise of the rights to purchase all Shares granted pursuant to this Option, such number of shares of Common Stock as shall, from time to time, be sufficient therefor. The Company covenants that all shares of Common Stock issuable upon exercise of this Option, upon receipt by the Company of the full Purchase Price therefor, shall be validly issued, fully paid and nonassessable.

34. Certain Adjustments.

(a) In case the Company shall at any time after the Grant Date (i) declare a dividend on the outstanding Common Stock payable in shares of its capital stock, (ii) subdivide the outstanding Common Stock, (iii) combine the outstanding Common Stock into a smaller number of shares, or (iv) issue any shares of its capital stock by reclassification of the Common Stock (including any such reclassification in connection with a consolidation or merger in which the Company is the continuing corporation), then, in each case, the Purchase Price, and the number of Shares issuable upon exercise of this Option, in effect at the time of the record date for such dividend or of the effective date of such subdivision, combination, or reclassification, shall be proportionately adjusted so that the Optionee after such time shall be entitled to receive the aggregate number and kind of shares which, if such Option had been exercised immediately prior to such time, he would have owned upon such exercise and been entitled to receive by virtue of such dividend, subdivision, combination, or reclassification. Such adjustment shall be made successively whenever any event listed above shall occur.

(b) Whenever there shall be an adjustment as provided in this Section 7, the Company shall promptly cause written notice thereof to be sent to the Optionee, which notice shall be accompanied by an officer's certificate setting forth the number of Shares purchasable upon the exercise of this Option and the Purchase Price after such adjustment and setting forth a brief statement of the facts requiring such adjustment and the computation thereof, which officer's certificate shall be conclusive evidence of the correctness of any such adjustment absent manifest error.

(c) The Company shall not be required to issue fractions of shares of Common Stock or other capital stock of the Company upon the exercise of this Option. If any fraction of a share would be issuable on the exercise of this Option, the Company shall


purchase such fraction for an amount in cash equal to the same fraction of the Purchase Price on the date of exercise of this Option.

35. Adjustments for Corporate Reorganization. If this Option is assumed by the surviving entity or affiliate thereof in any Corporate Reorganization, and such Corporate Reorganization is effected in such a way that holders of Common Stock shall be entitled to receive stock, securities, cash or assets with respect to or in exchange for Common Stock, then, as a condition of such Corporate Reorganization, appropriate provision shall be made whereby the holder of this Option shall thereafter have the right to purchase and receive upon the basis and upon the terms and conditions specified in this Option, upon exercise this Option and in lieu of the Shares immediately theretofore purchasable and receivable upon the exercise of the rights represented hereby, such number, amount and like kind of shares of stock, securities, cash or assets as may be issued or payable pursuant to the terms of the Corporate Reorganization with respect to or in exchange for the number of shares of Common Stock immediately theretofore purchasable and receivable upon the exercise of the rights represented hereby as if such shares were outstanding immediately prior to the Corporate Reorganization, and in any such case appropriate provision shall be made with respect to the rights and interest of the holders (including, without limitation, provisions for adjustments of the Purchase Price and of the number of Shares purchasable and receivable upon the exercise of this Option) to the end that the provisions hereof shall thereafter be applicable, as nearly as may be practicable, in relation to any shares of stock or securities thereafter deliverable upon the exercise hereof.

36. Rights Prior to Exercise. Optionee will have no rights as a shareholder with respect to the Shares except to the extent that Optionee has exercised the Option and has been issued and received delivery of a certificate or certificates evidencing the Shares so purchased.

37. Relationship with Optionee. Nothing in this Agreement shall be construed as constituting a commitment, guarantee, agreement or understanding of any kind or nature that the Company shall employ or engage Optionee, nor shall this Agreement affect in any way the right of the Company to terminate the relationship between the Company and the Optionee at any time and for any reason.

38. Lock-Up. Optionee hereby agrees that he shall not, without the consent of the managing underwriter, sell, transfer, pledge, hypothecate or otherwise transfer or dispose of any Common Stock or other shares of stock of the Company then owned by Optionee for up to 180 days following the effective date of a registration statement (other than a registration statement relating to any employee benefit plan, or with respect to a corporate reorganization or other transaction under Rule 145 promulgated under the Securities Act of 1933) of the Company for a public offering. In order to enforce the foregoing covenant, the Company shall have the right to place restrictive legends on the certificates representing the shares subject to this Section and to impose stop transfer instructions with respect to the Common Stock.

39. Restrictions on Transferability. The Option shall not be transferable by Optionee otherwise than by will or by the laws of descent and distribution, and shall be


exercisable during Optionee's lifetime only by Optionee.

40. Further Restrictions on Exercise and Sale. Optionee acknowledges and understands that the Shares subject to this Option is not registered under the Securities Act of 1933 or under applicable state securities laws. The Option shall be subject to the requirement that if at any time the Board of Directors shall determine, in its discretion, that the listing, registration or qualification of the Shares subject to such Option upon any securities exchange or under any state or federal law, or the consent or approval of any government regulatory body, is necessary or desirable as a condition of, or in connection with, the granting of such Option or the exercise thereof, such Option may not be exercised in whole or in part unless such listing, registration, qualification, consent or approval shall have been effected or obtained free of any conditions not acceptable to the Board of Directors. The costs of any such listing, registration, qualification, consent or approval shall be paid by the Company. Alternatively, the Company shall not permit any exercise of this Option unless it receives such representations, factual assurances, and legal opinions as it may deem necessary to determine and document the availability of an exemption from registration under federal and state securities laws with respect to any particular issuance of shares under this Agreement. Further, the Board of Directors shall require that Shares issued in respect of any exercise of this Option shall bear such restrictions on further transfer as shall be necessary to insure the availability of any exemption so claimed.

41. General Provisions.

(a) This Agreement shall be construed and enforced in accordance with and governed by the laws of the State of Texas.

(b) This Agreement represents the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior written or oral agreements between the parties with respect to the subject matter hereof (including the Original Agreement). This Agreement may be modified or amended only in a writing signed by all parties hereto.

(c) The rights and obligations of the Company and Optionee hereunder shall be binding upon, inure to the benefit of and be enforceable against their respective successors and assigns, legal representatives and heirs. The rights of Optionee hereunder may be assigned only with the prior written consent of the Company.

(d) Either party's failure to enforce any provision or provisions of this Agreement shall not in any way be construed as a waiver of any such provision or provisions, nor prevent the party thereafter from enforcing each and every other provision of this Agreement. The rights granted the parties herein are cumulative and shall not constitute a waiver of any party's right to assert all other legal remedies available to it under the circumstances.

(e) The Company and Optionee agree, upon request, to execute any further documents or instruments necessary or desirable to carry out the purposes or intent of this Agreement.


[Signatures appear on following page]


IN WITNESS WHEREOF, the Company and Optionee have executed this Agreement as of the date first above written.

COMPANY:

HEALTH DISCOVERY CORPORATION

By: /s/ Stephen D. Barnhill
    --------------------------
    Stephen D. Barnhill
    Title: Chairman and C.E.O.

OPTIONEE:

/s/ Joe Fanelli
----------------------------------
Joe Fanelli


NON-QUALIFIED STOCK OPTION AGREEMENT

THIS NON-QUALIFIED STOCK OPTION AGREEMENT (this "Agreement") is made on this 30th day of October, 2003 (the "Grant Date"), by and between HEALTH DISCOVERY CORPORATION, a Texas corporation (the "Company"), and JOE FANELLI, a Georgia resident (the "Optionee").

RECITALS:

WHEREAS, the Company desires to grant to Optionee an option to purchase shares of the Company's no par value common stock ("Common Stock"), and Optionee desires to accept such grant;

NOW, THEREFORE, the parties hereto, intending to be legally bound, agree as follows:

42. Grant of Option. The Board of Directors hereby grants Optionee an option to purchase from the Company a total of six hundred thousand (600,000) shares of Common Stock, at the purchase price of $0.01 per share (the "Purchase Price"), in accordance with the terms and conditions stated in this Agreement. The shares of Common Stock subject to the option granted hereby are referred to below as the "Shares," and the option to purchase such Shares is referred to below as the "Option." The Option is not intended to qualify as an "incentive stock option" within the meaning of Section 422 of the Internal Revenue Code of 1986.

43. Vesting of Option. The Option shall vest and become exercisable on the Grant Date. The Option may be exercised at any time and from time to time to purchase up to the number of Shares as to which it is then vested and exercisable at any subsequent date prior to termination of the Option.

44. Termination of Option. The Option shall remain exercisable until the earliest to occur of the dates specified below, upon which date the Option shall terminate:

(a) The date all of the Shares are purchased pursuant to the terms of this Agreement;

(b) At 5:00 P.M., Eastern Standard Time, on the date Optionee ceases to serve as an employee of the Company (a "Termination of Relationship") for Cause (as defined below);

(c) At 5:00 P.M., Eastern Standard Time, on the nine-month anniversary of a Termination of Relationship for any reason other than Cause;

(d) At 5:00 P.M., Eastern Standard Time, on the last date specified in the notice described below in the event of a Corporate Reorganization (as defined below), except to the extent that the Option is assumed by the surviving entity or affiliate thereof in


connection with such Corporate Reorganization (provided that in the event of a Corporate Reorganization, the Company shall send Optionee prior written notice of the effectiveness of such event and the last day on which Optionee may exercise the Option); or

(e) At 5:00 P.M., Eastern Standard Time, on the tenth (10th) anniversary of the Grant Date.

Upon its termination, the Option shall have no further force or effect and Optionee shall have no further rights under the Option or to any Shares that have not been purchased pursuant to prior exercise of the Option.

As used in this Section 3, "Cause" means any of the following: (i) the conviction of Optionee of any felony or any crime or act of dishonesty, fraud or moral turpitude; (ii) the judicial determination of Optionee as civilly liable for any act of fraud, gross negligence or tortious misconduct involving the Company; (iii) any act or omission by Optionee which constitutes a material breach by Optionee of his obligations under any present or future written agreement of employment between Optionee and the Company (which has not been cured within 30 days after written notice of such failure from the Company to Optionee); (iv) use of illegal drugs, drunkenness or other substance abuse by Optionee; (v) insubordination, gross incompetence or willful misconduct by Optionee in the performance of his duties under any present or future written agreement of employment between Optionee and the Company; (vi) excessive absenteeism (more than 10 days during any twelve-month period) by Optionee not related to illnesses, sick leave or authorized vacations; or (vii) any other act or omission by Optionee (other than an act or omission resulting from the exercise by Optionee of good faith business judgment) which materially impairs the financial condition or business reputation of the Company or is otherwise materially detrimental to the Company. Any determination as to whether a Termination of Relationship has occurred shall be made by the Board of Directors in its good faith discretion

For purposes of this Agreement, a "Corporate Reorganization" shall mean any of the following events: (a) any person (as such term is defined in Section 13(d) of the Securities Exchange Act of 1934 (the "Exchange Act")), group, corporation or other entity (other than the Company or any subsidiary of the Company), purchases shares pursuant to a tender offer or exchange offer to acquire any Common Stock of the Company for cash, securities or any other consideration, provided that after consummation of the offer, the person, group, corporation or other entity in question is the beneficial owner (as such term is defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of fifty percent (50%) or more of the outstanding Common Stock of the Company; or (b) the shareholders of the Company approve (i) any consolidation or merger of the Company in which the Company is not the continuing or surviving corporation or pursuant to which shares of Common Stock would be converted into cash, securities or other property, or (ii) any sale, lease, exchange or other transfer (in one transaction or a series of related transactions) of all or substantially all of the assets of the Company

45. Exercise of Option.


(a) The Option may be exercised only by (i) Optionee's completion, execution and delivery to the Company of a notice of exercise and, if required by the Company, a subscription agreement as supplied by the Company, and (ii) the payment to the Company, pursuant to the terms of this Agreement, of an amount equal to the Purchase Price multiplied by the number of Shares being purchased as specified in Optionee's notice of exercise (which Purchase Price may be paid to the Company in cash or by Optionee's execution and delivery to the Company of a promissory note mutually acceptable to the Company and the Optionee). Optionee must provide notice of exercise of the Option with respect to no fewer than 100 Shares (or any lesser number of Shares with respect to which the Option is vested and exercisable). Notwithstanding anything to the contrary in this Agreement, the Option may be exercised only if compliance with all applicable federal and state securities laws can be effected.

(b) Upon any exercise of the Option by Optionee or as soon thereafter as is practicable, the Company shall issue and deliver to Optionee a certificate or certificates evidencing such number of Shares as Optionee has then elected to purchase. Such certificate or certificates shall be registered in the name of Optionee and shall bear any legend required by any federal or state securities laws.

46. Shares Reserved. The Company shall at all times from and after the Grant Date reserve and keep available out of its authorized and unissued Common Stock, solely for the purpose of providing for the exercise of the rights to purchase all Shares granted pursuant to this Option, such number of shares of Common Stock as shall, from time to time, be sufficient therefor. The Company covenants that all shares of Common Stock issuable upon exercise of this Option, upon receipt by the Company of the full Purchase Price therefor, shall be validly issued, fully paid and nonassessable.

47. Certain Adjustments.

(a) In case the Company shall at any time after the Grant Date (i) declare a dividend on the outstanding Common Stock payable in shares of its capital stock, (ii) subdivide the outstanding Common Stock, (iii) combine the outstanding Common Stock into a smaller number of shares, or (iv) issue any shares of its capital stock by reclassification of the Common Stock (including any such reclassification in connection with a consolidation or merger in which the Company is the continuing corporation), then, in each case, the Purchase Price, and the number of Shares issuable upon exercise of this Option, in effect at the time of the record date for such dividend or of the effective date of such subdivision, combination, or reclassification, shall be proportionately adjusted so that the Optionee after such time shall be entitled to receive the aggregate number and kind of shares which, if such Option had been exercised immediately prior to such time, he would have owned upon such exercise and been entitled to receive by virtue of such dividend, subdivision, combination, or reclassification. Such adjustment shall be made successively whenever any event listed above shall occur.

(b) Whenever there shall be an adjustment as provided in this
Section 6, the


Company shall promptly cause written notice thereof to be sent to the Optionee, which notice shall be accompanied by an officer's certificate setting forth the number of Shares purchasable upon the exercise of this Option and the Purchase Price after such adjustment and setting forth a brief statement of the facts requiring such adjustment and the computation thereof, which officer's certificate shall be conclusive evidence of the correctness of any such adjustment absent manifest error.

(c) The Company shall not be required to issue fractions of shares of Common Stock or other capital stock of the Company upon the exercise of this Option. If any fraction of a share would be issuable on the exercise of this Option, the Company shall purchase such fraction for an amount in cash equal to the same fraction of the Purchase Price on the date of exercise of this Option.

48. Adjustments for Corporate Reorganization. If this Option is assumed by the surviving entity or affiliate thereof in any Corporate Reorganization, and such Corporate Reorganization is effected in such a way that holders of Common Stock shall be entitled to receive stock, securities, cash or assets with respect to or in exchange for Common Stock, then, as a condition of such Corporate Reorganization, appropriate provision shall be made whereby the holder of this Option shall thereafter have the right to purchase and receive upon the basis and upon the terms and conditions specified in this Option, upon exercise this Option and in lieu of the Shares immediately theretofore purchasable and receivable upon the exercise of the rights represented hereby, such number, amount and like kind of shares of stock, securities, cash or assets as may be issued or payable pursuant to the terms of the Corporate Reorganization with respect to or in exchange for the number of shares of Common Stock immediately theretofore purchasable and receivable upon the exercise of the rights represented hereby as if such shares were outstanding immediately prior to the Corporate Reorganization, and in any such case appropriate provision shall be made with respect to the rights and interest of the holders (including, without limitation, provisions for adjustments of the Purchase Price and of the number of Shares purchasable and receivable upon the exercise of this Option) to the end that the provisions hereof shall thereafter be applicable, as nearly as may be practicable, in relation to any shares of stock or securities thereafter deliverable upon the exercise hereof.

49. Rights Prior to Exercise. Optionee will have no rights as a shareholder with respect to the Shares except to the extent that Optionee has exercised the Option and has been issued and received delivery of a certificate or certificates evidencing the Shares so purchased.

50. Relationship with Optionee. Nothing in this Agreement shall be construed as constituting a commitment, guarantee, agreement or understanding of any kind or nature that the Company shall employ or engage Optionee, nor shall this Agreement affect in any way the right of the Company to terminate the relationship between the Company and the Optionee at any time and for any reason.

51. Lock-Up. Optionee hereby agrees that he shall not, without the consent of the managing underwriter, sell, transfer, pledge, hypothecate or otherwise transfer or dispose


of any Common Stock or other shares of stock of the Company then owned by Optionee for up to 180 days following the effective date of a registration statement (other than a registration statement relating to any employee benefit plan, or with respect to a corporate reorganization or other transaction under Rule 145 promulgated under the Securities Act of 1933) of the Company for a public offering. In order to enforce the foregoing covenant, the Company shall have the right to place restrictive legends on the certificates representing the shares subject to this Section and to impose stop transfer instructions with respect to the Common Stock.

52. Restrictions on Transferability. The Option shall not be transferable by Optionee otherwise than by will or by the laws of descent and distribution, and shall be exercisable during Optionee's lifetime only by Optionee.

53. Further Restrictions on Exercise and Sale. Optionee acknowledges and understands that the Shares subject to this Option is not registered under the Securities Act of 1933 or under applicable state securities laws. The Option shall be subject to the requirement that if at any time the Board of Directors shall determine, in its discretion, that the listing, registration or qualification of the Shares subject to such Option upon any securities exchange or under any state or federal law, or the consent or approval of any government regulatory body, is necessary or desirable as a condition of, or in connection with, the granting of such Option or the exercise thereof, such Option may not be exercised in whole or in part unless such listing, registration, qualification, consent or approval shall have been effected or obtained free of any conditions not acceptable to the Board of Directors. The costs of any such listing, registration, qualification, consent or approval shall be paid by the Company. Alternatively, the Company shall not permit any exercise of this Option unless it receives such representations, factual assurances, and legal opinions as it may deem necessary to determine and document the availability of an exemption from registration under federal and state securities laws with respect to any particular issuance of shares under this Agreement. Further, the Board of Directors shall require that Shares issued in respect of any exercise of this Option shall bear such restrictions on further transfer as shall be necessary to insure the availability of any exemption so claimed.

54. General Provisions.

(a) This Agreement shall be construed and enforced in accordance with and governed by the laws of the State of Texas.

(b) This Agreement represents the entire agreement between the parties with respect to the subject matter hereof and may be modified or amended only in a writing signed by all parties hereto.

(c) The rights and obligations of the Company and Optionee hereunder shall be binding upon, inure to the benefit of and be enforceable against their respective successors and assigns, legal representatives and heirs. The rights of Optionee hereunder may be assigned only with the prior written consent of the Company.

(d) Either party's failure to enforce any provision or provisions of this


Agreement shall not in any way be construed as a waiver of any such provision or provisions, nor prevent the party thereafter from enforcing each and every other provision of this Agreement. The rights granted the parties herein are cumulative and shall not constitute a waiver of any party's right to assert all other legal remedies available to it under the circumstances.

(e) The Company and Optionee agree, upon request, to execute any further documents or instruments necessary or desirable to carry out the purposes or intent of this Agreement.

[Signatures appear on following page]


IN WITNESS WHEREOF, the Company and Optionee have executed this Agreement as of the date first above written.

COMPANY:

HEALTH DISCOVERY CORPORATION

By: /s/ Stephen D. Barnhill
--------------------------------
Title: Chairman and C.E.O.

OPTIONEE:

/s/ Joe Fanelli
-----------------------------------
Joe Fanelli


EXHIBIT 10.2

ASSET PURCHASE AND SALE AGREEMENT

THE SECURITIES TRANSFERRED HEREIN AS PART OF THE PURCHASE PRICE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), OR ANY STATE SECURITIES LAWS IN RELIANCE ON ONE OR MORE EXEMPTIONS THEREUNDER AND MAY NOT BE SOLD OR TRANSFERRED EXCEPT IN TRANSACTIONS EXEMPT FROM REGISTRATION UNDER THE SECURITIES ACT OR ANY APPLICABLE STATE SECURITIES LAWS OR PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT THEREUNDER.

This Asset Purchase and Sale Agreement (together with all Exhibits and Schedules hereto, the "Agreement") is entered into as of the 15th day of September, 2003 (the "Closing Date") by and among DIRECT WIRELESS COMMUNICATIONS, INC., a Texas public corporation (together with its successors and permitted assigns, "Buyer"), BARNHILL GROUP, LLC, a Georgia limited liability company with its principal place of business and company headquarters at 2 Springfield Place, Savannah, Georgia 31411 ("Company") and STEVEN BARNHILL ("Barnhill") (hereinafter sometimes referred to collectively as the "Sellers" and individually as a "Seller"). (Buyer, Company and Seller are hereinafter sometimes referred to collectively as the "Parties" and individually as a "Party.")

WHEREAS, Seller is the owner of 100% of the issued and outstanding membership units of the Company and has the required and necessary authority to enter into this Agreement on behalf of the Company; and

WHEREAS, the Company is engaged in the business of Consulting (the "Business"); and

WHEREAS, Buyer is a publicly traded company engaged in, among other things, the acquisition of companies involved in medical technology and development; and

WHEREAS, Seller desires to sell, and Buyer desires to purchase, the Company's assets listed on Schedule 1.3 (the "Company Assets"), so that Buyer shall be the sole holder of the Company Assets, for the consideration, upon the terms, and subject to the conditions hereinafter set forth;

NOW, THEREFORE, in consideration of the premises, the provisions and the respective covenants and agreements set forth in this Agreement, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows:

ARTICLE 1. PURCHASE AND SALE OF COMPANY ASSETS; SELLER'S RETAINED ASSETS; DELIVERIES.

1.1. Sale and Purchase of Company Assets. Upon the terms and subject to the representations, warranties, covenants and conditions set forth herein, Seller hereby sells, grants, conveys, assigns, transfers and delivers to Buyer, and Buyer purchases and acquires from Seller, all right, title and interest of Seller in and to the Company Assets, free and clear of all claims, security interests, liens and encumbrances, restrictions, rights of others of any kind or character, for the consideration described and payable as set forth in Section 1.2 hereof.


1.2 Purchase Price.

1.2.1 Purchase Price. Upon the terms and subject to the conditions set forth herein, in consideration for the sale, grant, conveyance, assignment, transfer and delivery of the Company Assets, Buyer agrees to pay and deliver to Seller 29,825,564 shares of the common stock of Buyer ("Purchase Price").

1.2.2 Delivery. The parties stipulate and agree that the shares representing the Purchase Price have been transferred and delivered to Seller.(1)

1.3. Company Assets. The Company Assets are those assets listed on Schedule 1.3.

1.4. Seller's Retained Assets. The "Seller's Retained Assets" are all assets of the Company and Barnhill other than the Company Assets set forth on Schedule 1.3, and none of Seller's Retained Assets shall be transferred or otherwise affected by this Agreement.

1.5 Other Deliveries by Seller and Company to Buyer. At the Closing, Seller shall deliver or cause to be delivered to Buyer:

(a) All such bills of sale, deeds, assignments and other documents and instruments of sale, assignment, conveyance and transfer, as Buyer or its counsel may deem necessary or desirable to effect the transfer of the Company Assets to Buyer;

(b) A certificate executed by an officer of the Company dated as of the Closing Date, certifying that all representations and warranties of such Company and Seller herein contained are true, correct and complete in all material respects, and that such Company and Seller each has performed or complied in all material respects with all of the covenants and obligations required by this Agreement to be performed or complied with by each of them on or prior to the Closing Date;

(c) An executed original of each consent required to be obtained;

(d) The disclosure schedules required by this Agreement (the "Disclosure Schedules");

(e) The Stephen Barnhill Employment Agreement executed by Stephen Barnhill;2 and

(f) Such other instruments and documents as are required by any other provisions of this Agreement to be delivered on the Closing Date by Seller to Buyer.

1.6 Deliveries by Buyer to Seller. At the Closing, Buyer shall deliver or cause to be delivered to Seller and the Company.

(a) The Purchase Price in accordance with Section 1.2.1;

(b) A certificate executed by an officer of Buyer, dated as of the Closing Date, certifying that all representations and warranties of Buyer herein contained are true, correct and complete in all material respects as of the Closing Date, and that Buyer has performed or complied in all material respects with all of the covenants and obligations required by this Agreement to be performed or complied with by Buyer on or prior to the Closing Date;


(1) In whose name are the shares issued? Barnhill Group, LLC?
(2) Status?

(c) The Stephen Barnhill Employment Agreement executed by Buyer;

(d) Such other instruments and documents as are required by any other provisions of this Agreement to be delivered on the Closing Date by Buyer to Seller or Company.

1.7. Directors and Officers of the Buyer After Effective Date After the Closing Date, the following persons shall become officers and directors of Buyer until such time as they may be replaced in accordance with the Bylaws of the

Company: [Walker to confirm logistics]

         Officers:  Bill G. Williams        Chairman and Chief Executive Officer
                    Stephen Barnhill        President
                    Robert S. Braswell, IV  Vice President/Compliance Officer
                    W. Steven Walker        Secretary

         Directors: Bill G. Williams
                    Stephen Barnhill
                    Robert S. Braswell, IV
                    W. Steven Walker
                    -------------------
                    -------------------

ARTICLE 2. REPRESENTATIONS AND WARRANTIES OF SELLER.

2.1 Ownership of the Company Assets. Seller is the sole owner, beneficially and of record, of all of the Company Assets, free and clear of any pledge, lien, security interest, encumbrance or claim of any kind other than those listed on Schedule 2.1 hereto.3 Upon delivery of the Company Assets to Buyer pursuant to this Agreement, Buyer will receive good and marketable title thereto, free and clear of any pledge, lien, security interest, encumbrance or claim of any kind other than those listed on Schedule 2.1 hereto.

2.2 Authorization, Validity and Effect of Agreements.

(a) The Company has the requisite power and authority necessary to execute and deliver this Agreement and the agreements contemplated hereby, and to perform its obligations hereunder and thereunder. The execution and delivery of this Agreement and all agreements and documents contemplated hereby by the Company, and the consummation by the Company of the transactions contemplated hereby, have been duly authorized and approved by all requisite action on the part of the Company.

(b) This Agreement constitutes, and all agreements and documents contemplated hereby, when executed and delivered pursuant hereto, for value received, will constitute, the valid and legally binding obligations of Seller and the Company enforceable in accordance with their terms, except that enforceability may be limited by applicable bankruptcy, insolvency, reorganization or other laws of general application now or hereafter in effect relating to the enforcement of creditors' rights generally and by general principles of equity (whether in a proceeding at law or in equity).


(3) Are there any transfer restrictions related to the Fractal Units in the Operating Agreement?

(c) Except as set forth on Schedule 2.2, the execution and delivery of this Agreement by Seller and the Company does not, and the consummation of the transactions contemplated hereby by such Seller and the Company will not (i) require the consent, approval or authorization of, or declaration, filing or registration with, any governmental or regulatory authority or any third party;
(ii) result in the breach of any term or provision of, or constitute a default under, or result in the acceleration of or entitle any party to accelerate (whether after the giving of notice or the lapse of time or both) any obligation under, or result in the creation or imposition of any lien, charge, pledge, security interest or other encumbrance upon any part of the property of the Company pursuant to any provision of, any indenture, mortgage, lease, license, franchise, permit, authorization, lien, trust, or other agreement or instrument to which Seller or the Company is bound; (iii) violate or conflict with any provision of the Company's organizational documents, as amended to the date hereof; (iv) result in the violation of any statute, rule, regulation, ordinance, code, order, judgment, writ, injunction, decree, or arbitration award, or an event which with notice, lapse of time or both, would result in any such violation.

2.3 No Undisclosed Liabilities. Except as set forth on Schedule 2.3, on the Closing Date, the Company Assets had no liens or encumbrances, liabilities, liens or claims, of the type which should be disclosed. Additionally, there are no facts, conditions or circumstances, known to Seller or the Company, that will or may reasonably be expected to cause, either presently or with the passage of time, a "material adverse change" in the condition (financial or otherwise), of the Company Assets.

2.4 Consents. Except as disclosed on Schedule 2.4, no consent, approval, order or authorization of, or registration, declaration or filing with, any governmental authority or other entity is required to be obtained or made by Seller or the Company in connection with the execution and delivery of this Agreement or the performance of the obligations hereunder.

2.5 Broker's or Consultant's Fees. Each of Seller and the Company represents and warrants that each has dealt with no broker, finder or similar consultant in connection with the transaction contemplated by this Agreement, and, consequently, that no commission or finder's fee is due or payable in connection herewith.

2.6 No Untrue Statement. No representation or warranty of the Seller or Company contained herein nor any written information, exhibits, schedules or agreements furnished by or on behalf of Seller or Company pursuant to this Agreement or in connection with the transaction contemplated herein contains or shall contain any untrue statement of a material fact, or omit or shall omit to state a material fact necessary to make the statements and facts contained therein not misleading. Except as set forth on Schedule 2.6, there is no fact known to Seller or the Company which materially adversely affects, or in the future may materially adversely affect, individually or in the aggregate, the condition (financial or otherwise), assets, liabilities, business, operations or prospects of the Company, that has not been set forth herein or heretofore communicated to Buyer in writing.

ARTICLE 3. REPRESENTATIONS AND WARRANTIES OF BUYER

As an inducement to Seller to enter into and perform this Agreement, and in consideration of the covenants of Seller contained herein, Buyer represents and warrants to Seller, which representations and warranties shall survive the Closing, as follows:


3.1 Existence; Good Standing. Buyer is a corporation duly incorporated, validly existing, and in good standing under the laws of the State of Texas and in each jurisdiction where either the conduct of its business or ownership of its properties requires qualification to do business.

3.2 Authority. The Buyer has the requisite power and authority necessary to execute and deliver this Agreement, and the agreements contemplated hereby, and to perform its obligations hereunder and thereunder. The execution and delivery of this Agreement and all other documents contemplated hereby by Buyer, and the consummation by it of the transactions contemplated hereby, have been duly authorized by all requisite corporate action.

3.3 Enforceability. This Agreement, together with the documents contemplated hereby, and the Barnhill Employment Agreement, each when executed and delivered, constitute, the valid and legally binding obligations of Buyer enforceable in accordance with their terms, except that enforceability may be limited by applicable bankruptcy, insolvency, or other similar laws of general application now or hereafter in effect relating to the enforcement of creditors' rights generally and by principles of equity (whether in a proceeding at law or in equity).

3.4 No Consents or Breaches. The execution and delivery of this Agreement by Seller and the Company does not, and the consummation of the transactions contemplated hereby by such Seller and the Company will not (i) except as set forth on Schedule 3.44 hereof, require the consent, approval or authorization of, or declaration, filing or registration with, any governmental or regulatory authority or any third party; (ii) result in the breach of any term or provision of, or constitute a default under, or result in the acceleration of or entitle any party to accelerate (whether after the giving of notice or the lapse of time or both) any obligation under, or result in the creation or imposition of any lien, charge, pledge, security interest or other encumbrance upon any part of the property of the Company pursuant to any provision of, any indenture, mortgage, lease, license, franchise, permit, authorization, lien, trust, or other agreement or instrument to which Seller or the Company is bound; (iii) violate or conflict with any provision of the Company's organizational documents, as amended to the date hereof; (iv) result in the violation of any statute, rule, regulation, ordinance, code, order, judgment, writ, injunction, decree, or arbitration award, or an event which with notice, lapse of time or both, would result in any such violation.

3.5 Broker's or Consultant's Fees. Buyer represents and warrants that it has dealt with no broker, finder or similar consultant in connection with the transaction contemplated by this Agreement, and, consequently, that no commission or finder's fee is due or payable in connection herewith.

3.6 Consents. Except as disclosed on Schedule 3.6, no consent, approval, order or authorization of, or registration, declaration or filing with, any governmental authority or other entity is required to be obtained or made by any Buyer in connection with the execution and delivery of this Agreement or the performance of the obligations hereunder.

3.7 No Untrue Statement. No representation or warranty of Buyer contained herein nor any written information, exhibits, schedules or agreements furnished by or on behalf of Buyer pursuant to this Agreement or in connection with the transaction contemplated herein contains or shall contain any untrue statement of a material fact, or omit or shall omit to state a material fact necessary to make the statements and facts contained therein not misleading. There is no fact known to Buyer which materially adversely affects, or in the future may materially adversely affect, individually or in the aggregate, the condition (financial or otherwise), assets, liabilities, business, operations or prospects of Buyer, that has not been set forth herein or heretofore communicated to Buyer in writing.


* What is on this schedule?

3.8 Capitalization. The authorized capital stock of the Buyer consists of 200,000,000 shares of no par value common stock, of which 59,751,128 shares are issued and outstanding. Except as set forth on Schedule 3.8: (i) no options, warrants, subscriptions, puts, calls or other rights, commitments, undertakings or understandings granted by the Buyer to acquire, dispose of or restrict the transfer of, any of the Buyer's capital stock or other securities of any kind or class or rights, obligations or undertakings convertible into securities of any kind or class of the Buyer are authorized or outstanding; (ii) the Buyer is not subject to any obligation to purchase, redeem or otherwise acquire any of its capital stock or securities (or of any options or rights or obligations described in the preceding clause (i)) upon the occurrence of a specified event (and assuming that specified time periods have passed and appropriate notices have been given) or otherwise and (iii) no other kind or class of capital stock except as described in this Section 3.8 is authorized or outstanding. All issued and outstanding shares of the Buyer (other than those issued to the Company) have been duly authorized and validly issued and are fully paid and nonassessable, were not issued in violation of any preemptive rights and were issued in compliance with all applicable federal and state securities laws. The shares of the Buyer issued and delivered to the Company as described in Section 1.2, and upon delivery of the Company Assets as provided in this Agreement, are duly authorized, validly issued, fully paid and nonassessable and not subject to preemptive rights created by statute, the Buyer's Articles of Incorporation or bylaws or any agreement to which Buyer is a party or is bound.

3.9 Absences of Undisclosed Liabilities. Except as and to the extent reflected in or reserved against in the Buyer's financial statements, the Buyer has no other liabilities of any nature (whether accrued, absolute, contingent, changing, known, unknown, determinable, indeterminable, liquidated, unliquidated or otherwise and whether due or to become due) relating to any existing or prior act, omission, condition or state of facts that would materially affect the Buyer's business, financial condition or results of operations.

3.10 Litigation. The Buyer (a) is not (and since December 31, 2002 has not been) engaged in, a party to, subject to or threatened with any claim, controversy, legal or equitable action or other proceeding (whether as plaintiff, defendant or otherwise); and (b) is not (and since December 31, 2002 has not been) a party to or subject to any judgment, order, decree or restriction against it.

3.11 Compliance with Laws. The Buyer is (and has been) in compliance in all material respects with all applicable law, including that involving antitrust, unfair competition, trade regulation, securities antipollution, environmental, employment and plant downsizing, relocation, closing or safety. The Buyer is not (and since December 31, 2002 has not been) either charged with, in receipt of any notice of, or under investigation with respect to any material failure or alleged material failure to comply with any provision of any applicable law that has had or that could be reasonably expected to have a material adverse effect on the assets owned, leased or currently used by the Buyer or on the Buyer's business, financial condition or results of operations.

3.12 Financial Statements. The financial statements of Buyer contained in its public filings made with the Securities and Exchange (i) have been prepared from and in accordance with the books and records of Buyer and in conformity with United States generally accepted accounting principles, consistently applied, in effect at the date of such financial statement ("GAAP") and (ii) such financial statements present fairly in accordance with GAAP the consolidated financial position and results of operations and cash flows of Buyer as of their respective dates and for the respective periods covered thereby.


3.13 Change in Control Provisions. The Buyer is not a party nor subject to any agreement that contains any provisions that become effective or are accelerated or contingent upon a change in control of the Buyer or otherwise require any payment or performance by the Buyer or any officer, director or shareholder thereof, now or in the future, in connection with or as a result of any of the transactions contemplated by this Agreement.

ARTICLE 4. CONDITIONS PRECEDENT TO BUYER'S OBLIGATIONS.

The obligations of Buyer to purchase and pay for the Company Assets shall be subject to and conditioned upon, at Buyer's option, the satisfaction as of the Closing Date of each of the following conditions:

4.1 Accuracy of Representations and Warranties. All representations and warranties of Seller and the Company contained herein shall be true and correct in all material respects at and as of the Closing Date.

4.2 Compliance with Agreement. Seller and the Company shall have performed all agreements and covenants and satisfied all conditions on their part to be performed or satisfied by the Closing Date pursuant to the terms hereof.

4.3 Reasonable Access; Investigation. The Company shall have allowed Buyer during regular business hours, through its employees, agent and representatives, to make such investigation of the business, properties, plant, books and records of Company and to conduct such examination of the condition (financial or otherwise) of Company as Buyer deems necessary or advisable to familiarize itself with such business, properties, plant, books, records, condition and other matters. Buyer shall be satisfied, in its sole discretion, with the results of its investigation of the business, properties, plant, books and records of the Company.

4.4 Employment Agreement with Stephen Barnhill. Buyer shall have concluded an employment agreement on terms and conditions satisfactory to Buyer in its sole discretion with Stephen Barnhill.

4.5 Consents. All notices, consent, approvals and waivers, if any, described in Schedule 2.4, necessary to the consummation of the transactions contemplated herein required in order to prevent a default or termination under the terms of any agreement to which any of the Seller or the Company is a party or is bound shall be obtained and shall remain in full force and effect at and as of the Closing Date.

4.6 No Adverse Proceedings. No law shall have been enacted or promulgated, and no suit, action, investigation, inquiry or other proceeding by any governmental body or other person or legal administrative proceeding shall have been instituted or threatened which questions the validity or legality of the transactions contemplated hereby, seeks to restrain or prohibit the transactions contemplated hereby, or which claims, or might give rise to a claim for, damages against Buyer as a result of the consummation of the transactions, or which in Buyer's judgment imposes or may impose undue burdens upon the Company or the Buyer.

4.7 UCC, Tax Lien and Judgment Search Results. Buyer shall have obtained, at Buyer's sole cost and expense, a report, in form and substance satisfactory to Buyer, as to the results


of an examination of financing statements filed under the Uniform Commercial Code, and tax lien and judgment records, in each office in each such jurisdiction as Buyer shall require, and such report shall indicate no material security interests, tax liens, judgments or other liens not previously disclosed in writing to Buyer with respect to the Company Assets.

4.8 Required Documents. Seller shall have delivered all reports, agreements, certificates, instruments, opinions and other documents required by this Agreement to be delivered by Seller on the Closing Date, and the form and substance of all such reports, agreements, certificates, instruments, opinions and other documents shall be reasonably satisfactory to Buyer.

ARTICLE 5. CONDITIONS PRECEDENT TO SELLER'S AND COMPANY'S OBLIGATIONS

The obligations of Seller to sell, grant, convey, assign, transfer and deliver the Company Assets and for Seller and the Company otherwise to perform their respective obligations hereunder shall be subject to and conditioned upon, at Seller's and the Company's option, the satisfaction of each of the following conditions:

5.1 Representations and Warranties. All representations and warranties of Buyer contained herein shall be true and correct in all material respects at and as of the Closing Date.

5.2 Compliance with Agreement. Buyer shall have performed all agreements and covenants and satisfied all conditions on its part to be performed or satisfied by the Closing Date pursuant to the terms hereof.

5.3 No Adverse Proceedings. No law shall have been enacted or promulgated, and no suit, action, investigation, inquiry or other proceeding by any governmental body or other person or legal administrative proceeding shall have been instituted or threatened which questions the validity or legality of the transactions contemplated hereby, seeks to restrain or prohibit the transactions contemplated hereby, or which claims, or might give rise to a claim for, damages against Buyer as a result of the consummation of the transactions, or which in Buyer's judgment imposes or may impose undue burdens upon the Company or the Buyer.

5.4 Employment Agreement with Stephen Barnhill. Buyer shall have concluded an employment agreement on terms and conditions satisfactory to Buyer in its sole discretion with Stephen Barnhill.

5.5 Required Documents. Buyer shall have delivered all reports, agreements, certificates, instruments, opinions and other documents required by this Agreement to be delivered by Buyer on the Closing Date, and the form and substance of all such reports, agreements, certificates, instruments, opinions and other documents shall be reasonably satisfactory to Seller and the Company.

ARTICLE 6. INDEMNIFICATION; SURVIVAL OF REPRESENTATIONS AND WARRANTIES.

6.1 Survival of Representations and Warranties and Indemnity Obligations. All representations and warranties made by the Parties in this Agreement and the indemnification obligations contained in this Article 6 shall survive the execution hereof and the Closing Date, and shall survive until the expiration of any applicable statute of limitations plus a period of fifteen
(15) days.


6.2 Losses. "Losses" shall mean, for purposes of this Article 6, with respect to any person or party, any actual out-of-pocket payment, expense incurred or income loss resulting from any loss, liability, obligation, damage (including, without limitation, consequential, punitive, special or otherwise), deficiency, lien, claim, suit, cause of action, judgment, cost or expense (including, without limitation, reasonable attorneys' and accountants' fees and expenses and court costs of any kind, nature or description (regardless of whether the claim or threat of lawsuit matures into a lawsuit)).

6.3 Indemnification by Seller. Subject to the provisions of this Article 6, Seller, jointly and severally, shall indemnify, defend, protect, save and hold harmless Buyer and its officers, directors, employees and agents ("Seller Indemnified Parties") against, and will reimburse Buyer and/or any of the aforementioned indemnitees on demand for, any and all Losses made or incurred by or asserted against any of the Seller Indemnified Parties, at any time after the Closing Date, directly or indirectly, arising out of, related to, caused by, or resulting from any of the following ("Seller Indemnified Claims"):

any inaccuracy or misrepresentation in, omission from, or breach or nonfulfillment of, any representation, warranty, term, provision, or covenant by any of Seller and/or the Company contained in this Agreement, or in any Schedule or Exhibit hereto.

6.6 Indemnification by Buyer. Subject to the provisions of this Article 6, Buyer shall indemnify, defend, protect, save and hold harmless each Seller and their officers, directors, employees and agents ("Buyer Indemnified Parties" and with the Seller Indemnified Parties, the "Indemnified Parties") against, and will reimburse such Buyer Indemnified Parties on demand for, any and all Losses made or incurred by or asserted against any of the Buyer Indemnified Parties, at any time after the Closing Date, directly or indirectly, arising out of, related to, caused by, or resulting from any of the following ("Buyer Indemnified Claims"):

any inaccuracy, omission, misrepresentation in, omission from, or breach of nonfulfillment of any representation, warranty, term, provision, covenant or agreement on the part of Buyer contained in this Agreement or in any Schedule or Exhibit hereto.

6.7 Limitation on Liability. Notwithstanding the forgoing, the Indemnifying Party's obligations to indemnify the Indemnified Party against any Loss shall be subject to the following limitations:

(a) Threshold. No indemnification shall be made under Section 6.5 or 6.6 until the aggregate amount of Loss exceeds $25,000.00 (the "Threshold"), but if the aggregate amount of Loss thereunder exceeds $25,000.00, then indemnification shall be made by the Indemnifying Party thereunder to the full extent of Loss.

(b) Ceiling. Neither Seller nor Buyer shall be obligated to make indemnification payments by virtue of Section 6.6 or Section 6.7 to the extent Loss exceed $600,000.00.

6.8 Fraud; Intentional Misrepresentation. The limitations set forth in
Section 6.7 shall not apply to any Loss arising out of (i) fraud or (ii) the breach of any representation or warranty contained herein or pursuant hereto if such representation or warranty was made with actual knowledge that it contained an untrue statement of a fact or omitted to state a fact necessary to make the statements of facts contained therein not misleading.


ARTICLE 7. MISCELLANEOUS.

7.1 Notices. Any notice, consent, approval, request, demand, declaration or other communication required hereunder shall be in and shall be given and shall be deemed to have been received if (i) delivered in person with receipt acknowledged, (ii) telecopied and electronically confirmed during regular business hours of recipient at recipient's place of business, and if sent outside of regular business hours, such notice is deemed given on the next business day, (iii) delivered by a nationally recognized overnight courier for next business day delivery with receipt acknowledged, or (iv) four days after being placed in the federal mail, postage prepaid, certified or registered mail, return receipt requested.

7.2 Binding Effect; Benefits. This Agreement shall be binding upon and shall inure to the benefit of the Parties, the Indemnified Parties, and their respective successors and permitted assigns. Notwithstanding anything contained herein to the contrary, nothing in this Agreement, expressed or implied, is intended to confer on any person (other than the Parties, the Indemnified Parties, or their respective successors and permitted assigns) any rights, remedies, obligations or liabilities under or by reason of this Agreement.

7.3 No Third-party Beneficiaries. No person or entity not a Party to this Agreement shall be deemed to be a third-party beneficiary hereunder or entitled to any rights hereunder.

7.4 Entire Agreement; Amendment. This Agreement, together with the Exhibits, Schedules and other agreements and documents contemplated hereby, constitute the final written expression of all agreements between the Parties, and is a complete and exclusive statement of those terms. Except as specifically included or referred herein, this Agreement and the Exhibits, Schedules and other agreements and documents contemplated hereby supersede all prior understandings, negotiations and agreements concerning the matters specified herein, including without limitation the Letter Agreement, dated August 15, 2003, between Seller and Buyer. Any representations, promises, warranties or statements made by any Party that differ in any way from the terms of this written Agreement, and the Exhibits, Schedules and other agreements and documents contemplated hereby, shall be given no force or effect (except as specifically included or referred to herein). The Parties specifically represent, each to the others, that there are no additional or supplemental agreements between them related in any way to the matters herein contained unless specifically included or referred to herein. No addition to or modification of any provision hereof shall be binding upon any Party unless made in writing and signed by all Parties.

7.5 Governing Law. THIS AGREEMENT, AND ALL QUESTIONS RELATING TO ITS VALIDITY, INTERPRETATION, PERFORMANCE AND ENFORCEMENT (INCLUDING, WITHOUT LIMITATION, PROVISIONS CONCERNING LIMITATIONS OF ACTION), SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF TEXAS (EXCLUSIVE OF THE CONFLICT OF LAW PROVISIONS THEREOF) APPLICABLE TO AGREEMENTS MADE AND TO BE PERFORMED ENTIRELY WITHIN SUCH STATE.

7.6 Venue; Binding Arbitration. PURSUANT TO THE FEDERAL ARBITRATION
ACT, ALL DISPUTES ARISING OUT OF OR RELATED TO THIS AGREEMENT, INCLUDING BUT NOT LIMITED TO DISPUTES REGARDING THE VALIDITY OF THIS PROVISION, SHALL BE SUBMITTED EXCLUSIVELY TO BINDING ARBITRATION IN DALLAS, TEXAS, PURSUANT TO THE COMMERCIAL ARBITRATION RULES OF THE AMERICAN ARBITRATION ASSOCIATION, PROVIDED HOWEVER THAT A PARTY SHALL BE ENTITLED TO SEEK INJUNCTIVE RELIEF FROM A COURT OF JURISDICTION AGAINST BREACH


HEREOF OR IN AID OF ARBITRATION. THE PARTIES UNDERSTAND THAT THE AGREEMENT TO ARBITRATION CONSTITUTES A WAIVER OF TRIAL BY JURY. THE PARTIES IRREVOCABLY DESIGNATE AND CONSENT TO THE EXCLUSIVE AND MANDATORY PERSONAL JURISDICTION, VENUE AND FORUM OF THE FEDERAL AND STATE COURTS IN DALLAS, TEXAS, FOR ALL JUDICIAL RECOURSE ANCILLARY TO THE ARBITRATION, EXCEPT THAT the prevailing party in any arbitration shall be entitled to enforcement of the arbitral award in any court of competent jurisdiction.

7.7 Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be deemed an original but all of which shall constitute one and the same instrument.

7.8 Headings. Headings of the Sections and Articles of this Agreement are for the convenience of reference only, and shall be given no substantive or interpretive effect whatsoever.

7.9 Waivers. No wavier of any provision of this Agreement shall be valid or binding unless it is in writing, dated subsequent to the date hereof and signed by all Parties. No waiver of any breach, term or condition of this Agreement by any Party shall constitute a subsequent waiver of the same or any other breach, term or condition.

7.10 Severability. If for any reason whatsoever, any one or more of the provisions hereof shall be held or deemed to be illegal, inoperative, unenforceable or invalid, such determination shall not render any of the other provisions hereof illegal, inoperative, unenforceable or invalid, but this Agreement shall be construed as if such illegal, inoperative, unenforceable or invalid provisions had never been contained herein.

7.11 Assignability. Neither this Agreement nor any of the Parties' rights hereunder may be assigned by any Party without the prior written consent of the other Parties.

7.12 Construction. The Parties acknowledge that their respective attorneys have participated jointly in the drafting of this Agreement and that it has not been written solely by counsel for one Party. The Parties agree that the rule of construction to the effect that any ambiguities are to be or may be resolved against the drafting party shall not be employed in the interpretation of this Agreement to favor any Party against another.

7.13 Attorneys' Fees. The prevailing Party in any dispute between or among the Parties arising out of the interpretation, application or enforcement of any provision hereof shall be entitled to recover its reasonable attorneys' fees and costs whether suit be filed or not, including without limitation costs and attorneys' fees related to or arising out of any, trial or appellate proceedings.

7.14 Expenses. Except as specifically provided herein, each Party shall pay all of its own costs and expenses incurred or to be incurred in negotiating and preparing this Agreement and in effecting and carrying out the transactions contemplated hereby.

7.15 Further Actions. At any time and from time to time after the Closing Date, each Party hereto agrees, at its own expense (except as otherwise provided herein), to take such actions and to execute, acknowledge and deliver such documents as may be reasonably requested by another Party to effectuate the purposes of this Agreement.


IN WITNESS WHEREOF, the Parties have caused this Agreement to be duly executed by their respective duly authorized officers or agents, as the case may be, to be effective as of the day and year hereinabove first set forth.

BUYER:

DIRECT WIRELESS COMMUNICATIONS, INC.

By: /s/  Bill G Williams
         ---------------
         Bill G. Williams
         Chief Executive Officer

COMPANY:

BARNHILL GROUP, LLC,
A Georgia limited Liability Company

By: /s/  Stephen D. Barnhill
         -------------------
         Stephen D.Barnhill
         Manager

BARNHILL:

By: /s/  STEPHEN D. BARNHILL
         -------------------
         STEPHEN D. BARNHILL


SCHEDULE 1.3

1. 42,857 membership units of Fractal Genomics, LLC

E 47


SCHEDULE 2.1

1. The membership units of Fractal Genomics, LLC are subject to transfer restrictions set forth in the Operating Agreement of Fractal Genomics, LLC, dated September 1, 2003.

2. The membership units of Fractal Genomics, LLC have not been registered under the Securities Act of 1933, as amended, or any state securities law and are subject to the transfer restrictions related thereto.


SCHEDULE 2.2

1. See Schedule 2.1.


SCHEDULE 2.3

1. See Schedule 2.1.


SCHEDULE 2.4

1. Neither the Seller nor the Company is making any filing with the Securities and Exchange Commission, any other federal agency or any state agency with respect to the transfer of the membership units of Fractal Genomics, LLC.


SCHEDULE 2.6

Fractal Genomics, LLC is a high-risk, startup venture with no revenue. It intends to operate in a highly competitive market and compete against companies with greater financial and other resources. Initially, it will have negative operating income and may never become profitable. As a result, any financial projections are inherently uncertain and unreliable.


EXHIBIT 10.3

ASSET PURCHASE AND SALE AGREEMENT

THE SECURITIES ISSUED AS PART OF THE PURCHASE PRICE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), OR ANY STATE SECURITIES LAWS IN RELIANCE ON ONE OR MORE EXEMPTIONS THEREUNDER AND MAY NOT BE SOLD OR TRANSFERRED EXCEPT IN TRANSACTIONS EXEMPT FROM REGISTRATION UNDER THE SECURITIES ACT OR ANY APPLICABLE STATE SECURITIES LAWS OR PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT THEREUNDER.

This Asset Purchase and Sale Agreement (together with all Exhibits and Schedules hereto, the "Agreement") is entered into as of the 30th day of December, 2003 by and among HEALTH DISCOVERY CORPORATION (fka DIRECT WIRELESS COMMUNICATIONS, INC.), a Texas public corporation with its principal place of business and company headquarters at 1116 South Old Temple Road, Lorena, Texas 76655 (together with its successors and permitted assigns, "Buyer"), FRACTAL GENOMICS, LLC, a California limited liability company with its principal place of business and company headquarters at 111 Commonwealth Avenue, San Francisco, California 94118 ("Company") and SANDY SHAW ("Shaw") (Company and Shaw are hereinafter sometimes referred to collectively as the "Sellers" and individually as a "Seller"). (Buyer, Company and Seller are hereinafter sometimes referred to collectively as the "Parties" and individually as a "Party").

WHEREAS, Shaw is the owner of 51% of the issued and outstanding membership units of the Company and has the required and necessary authority to enter into this Agreement on behalf of the Company; and

WHEREAS, the Company is engaged in the business (the "Business") of development of Fractal Genomics Technology (as defined on Schedule 1.3 hereto); and

WHEREAS, Buyer is a publicly traded company engaged in, among other things, the acquisition of companies involved in medical technology and development; and

WHEREAS, Buyer and the Company entered into that certain binding letter agreement (the "Letter Agreement") dated August 29, 2003 pursuant to which Buyer purchased and Company is to sell Company Assets as defined herein and therein; and

WHEREAS, pursuant to such Letter Agreement, the parties now desire to enter into this definitive Agreement as contemplated under the terms of the Letter Agreement.

NOW, THEREFORE, in consideration of the premises, the provisions and the respective covenants and agreements set forth in this Agreement, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows:

ARTICLE 1. PURCHASE AND SALE OF COMPANY ASSETS; SELLER'S RETAINED ASSETS; DELIVERIES.

1.1. Sale and Purchase of Company Assets. Upon the terms and subject to the representations, warranties, covenants and conditions set forth herein, and effective on the date hereof (the "Effective Date"), Seller hereby sells, grants, conveys, assigns, transfers and delivers


to Buyer, and Buyer purchases and acquires from Seller, all right, title and interest of Seller in and to the Company Assets, free and clear of all claims, security interests, liens and encumbrances, restrictions, rights of others of any kind or character, for the consideration described and payable as set forth in Section 1.2 hereof.

1.2 Purchase Price.

1.2.1 Purchase Price. Upon the terms and subject to the conditions set forth herein, in consideration for the sale, grant, conveyance, assignment, transfer and delivery of the Company Assets, Buyer agrees to pay and deliver to Sellers 7,500,000 unregistered shares of the common stock of Buyer and the sum of $500,000 in accordance with the payment schedule set forth in paragraph 1.2.3 ("Purchase Price").

1.2.2 Delivery. The parties stipulate and agree that the 3,825,000 shares comprising a portion of the Purchase Price have been transferred and delivered to Shaw, and that no additional shares shall be issued for the reasons set forth in that certain Agreement and Memorandum between the Parties and certain other individuals of even date herewith.

1.2.3 Payment Schedule. The cash portion of the Purchase Price shall be payable as follows: Eight equal installments of $62,500 plus interest at the rate of six percent (6%) per annum with the initial payment due and payable on or before January 2, 2004 and thereafter on the following dates: April 1, 2004, July 1, 2004, October 1, 2004, January 1, 2005, April 1, 2005, July 1, 2005 and October 1, 2005. In the event that any payment of principal and interest is not made within 15 days after the due date thereof, then all of the then unpaid principal and relevant accrued interest shall become immediately due and payable.

1.2.4 Security for Performance. Buyer, to secure the prompt and faithful payment of the cash portion of the Purchase Price and to secure the rights of Seller described in Section 1.2.5 below, agrees to and does hereby grant to Seller a security interest in and to the Company Assets. In this respect the Seller or Buyer shall execute such financing statements or UCC-1's as may be necessary to properly perfect the security interest granted herein.

1.2.5 Default in Payment. From and after January 1, 2005, in the event that any portion of the cash payment (whether payable before or after January 1, 2005) is not paid when due and continues to be in arrears without cure for a period of sixty (60) days after notice from Seller or Shaw, the Company Assets assigned hereunder shall revert to Shaw as if such assignment had not been made.

1.3. Company Assets. The Company Assets purchased hereunder are all of the assets of the Company (other than Seller's Retained Assets) including without limitation all patents and patent rights, trademarks and trademark rights, trade names and trade name rights, domain names, service marks and service mark rights, service names and service name rights, brand names, inventions, processes, methods, designs, devices, tools, specifications, techniques, algorithms, formulae, improvements, copyrights and copyright rights, trade dress, business and product names, logos, slogans, trade secrets, industrial models, computer programs, software (whether in source or object code) and related documentation, technical information, manufacturing, engineering and technical drawings, know-how and all pending applications for and registrations of patents, trademarks, service marks and copyrights as relate to the Fractal Genomics Technology and the Business relating thereto (as defined in Schedule 1.3).


1.4. Seller's Retained Assets. The "Seller's Retained Assets" are all cash and cash equivalents and the membership units in Company owned by Shaw.

1.5 No Assumed Liabilities. Buyer shall not assume by virtue of this Agreement or the transactions contemplated hereby, and shall have no liability for, any liabilities of Seller (including, without limitation, those related to the Business) of any kind, character or description whatsoever, whether accrued, absolute or contingent, whether known or unknown, whether disclosed or undisclosed and regardless of when asserted (the "Retained Liabilities"). Seller shall discharge in a timely manner or shall make adequate provision for all of the Retained Liabilities.

1.6 License Agreement for Non-Medical Uses. Upon completion of the transaction contemplated hereby, Buyer will grant to Seller, under the terms and conditions of a license agreement (the "License Agreement"), the right and license to use and employ the Fractal Genomics Technology in non-medical applications. For the purpose of this Agreement, the term "non-medical applications" will mean all uses other than those applications involving, directly or indirectly, human diagnostic and treatment applications, pharmaceutical manufacture and development, plant, animal or human medical research and other applications which are generally referred to or known as "medical applications". Such License Agreement shall provide, at a minimum, the specific exclusions set forth herein, term, and royalty payable to Buyer hereunder (which royalty shall be four percent (4%) of the gross revenues attributable to such non-medical applications of the Fractal Genomics Technology).

1.7 Other Deliveries by Seller to Buyer. As of the Effective Date, Seller has delivered or caused to be delivered to Buyer:

(a) A Bill of Sale executed by each of the Sellers;

(b) Such other assignments and documents and instruments of sale, assignment, conveyance and transfer, as Buyer or its counsel may deem reasonably necessary or desirable to effect the transfer of the Company Assets to Buyer;

(c) A certificate, dated the Effective Date and executed by the Manager of the Company, in form and substance reasonably satisfactory to Buyer, as to the authenticity of the actions of the Managers and Members authorizing the transactions contemplated herein. A copy of the Company's Operating Agreement shall be attached to the certificate;

(d) The Sandy Shaw Employment Agreement executed by Sandy Shaw; and

(e) Such other instruments and documents as are required by any other provisions of this Agreement to be delivered on the Effective Date by Seller to Buyer.

1.8 Deliveries by Buyer to Seller. As of the Effective Date, Buyer has delivered or caused to be delivered to Seller and the Company.

(a) The Purchase Price in accordance with Section 1.2.1;

(b) A certificate, dated the Effective Date and executed by the Secretary of Buyer, in form and substance reasonably satisfactory to Seller, as to the authenticity of the actions of the Board of Directors of Buyer authorizing the transactions contemplated herein;

(c) The Sandy Shaw Employment Agreement executed by Buyer;


(d) Such other instruments and documents as are required by any other provisions of this Agreement to be delivered on the Effective Date by Buyer to Seller or Company.

1.9. Directors and Officers of the Buyer After Effective Date After the Effective Date, the following persons shall become officers and directors of Buyer until such time as they may be replaced in accordance with the Bylaws of the Company:

Officers:  Stephen D. Barnhill M.D.   Chairman & CEO
           David Cooper               President
           Robert S. Braswell, IV     Chief Administrative Officer/
                                      Secretary & Treasurer
           Sandy Shaw                 Vice President/Fractal Technology

Directors: Stephen D. Barnhill M.D.
           Robert S. Braswell, IV
           David Cooper

ARTICLE 2. REPRESENTATIONS AND WARRANTIES OF SELLERS. Sellers hereby jointly and severally represent and warrant to Buyer as follows, which representations and warranties shall survive the Closing:

2.1 Ownership of the Company Assets. Seller is the sole owner, beneficially and of record, of all of the Company Assets, free and clear of any pledge, lien, security interest, encumbrance or claim of any kind. Upon delivery of the Company Assets to Buyer pursuant to this Agreement, Buyer will receive good and marketable title thereto, free and clear of any pledge, lien, security interest, encumbrance or claim of any kind.

2.2 Authorization, Validity and Effect of Agreements.

(a) The Company has the requisite power and authority necessary to execute and deliver this Agreement and the agreements contemplated hereby, and to perform its obligations hereunder and thereunder. The execution and delivery of this Agreement and all agreements and documents contemplated hereby by the Company, and the consummation by the Company of the transactions contemplated hereby, have been duly authorized and approved by all requisite action on the part of the Company.

(b) This Agreement constitutes, and all agreements and documents contemplated hereby, when executed and delivered pursuant hereto, will constitute, the valid and legally binding obligations of Shaw and the Company enforceable in accordance with their terms, except that enforceability may be limited by applicable bankruptcy, insolvency, reorganization or other laws of general application now or hereafter in effect relating to the enforcement of creditors' rights generally and by general principles of equity (whether in a proceeding at law or in equity).

(c) The execution and delivery of this Agreement by Shaw and the Company does not, and the consummation of the transactions contemplated hereby by Shaw and the Company will not (i) require the consent, approval or authorization of, or declaration, filing or registration with, any governmental or regulatory authority or any third party; (ii) result in the breach of any term or provision of, or constitute a default under, or result in the acceleration of or


entitle any party to accelerate (whether after the giving of notice or the lapse of time or both) any obligation under, or result in the creation or imposition of any lien, charge, pledge, security interest or other encumbrance upon any part of the property of the Company pursuant to any provision of, any indenture, mortgage, lease, license, franchise, permit, authorization, lien, trust, or other agreement or instrument to which Shaw or the Company is bound; (iii) violate or conflict with any provision of the Company's organizational documents, as amended to the date hereof; (iv) result in the violation of any statute, rule, regulation, ordinance, code, order, judgment, writ, injunction, decree, or arbitration award, or an event which with notice, lapse of time or both, would result in any such violation.

(d) Company is a limited liability company duly organized, validly existing and in good standing under the laws of California and is duly qualified in each jurisdiction where either the conduct of its business or ownership of its properties requires qualification to do business, and has full corporate power and authority to conduct the Business as and to the extent now conducted and to own, use and lease its assets and properties used in the Business.

2.3 No Undisclosed Liabilities. On the Effective Date, the Company Assets will not be subject to any liens, encumbrances, liabilities or claims. Additionally, there are no facts, conditions or circumstances, known to Shaw or the Company, that will or may reasonably be expected to cause, either presently or with the passage of time, a "material adverse change" in the condition (financial or otherwise), of the Company Assets.

2.4 Consents. No consent, approval, order or authorization of, or registration, declaration or filing with, any governmental authority or other entity is required to be obtained or made by Shaw or the Company in connection with the execution and delivery of this Agreement or the performance of the obligations hereunder.

2.5 Broker's or Consultant's Fees. Each of Seller and the Company represents and warrants that each has dealt with no broker, finder or similar consultant in connection with the transaction contemplated by this Agreement, and, consequently, that no commission or finder's fee is due or payable in connection herewith.

2.6 No Untrue Statement. No representation or warranty of either Seller contained herein nor any written information, exhibits, schedules or agreements furnished by or on behalf of either Seller pursuant to this Agreement or in connection with the transaction contemplated herein contains or shall contain any untrue statement of a material fact, or omit or shall omit to state a material fact necessary to make the statements and facts contained therein not misleading. Except as set forth on Schedule 2.6, there is no fact known to either Seller which materially adversely affects, or in the future may materially adversely affect, individually or in the aggregate, the condition (financial or otherwise), assets, liabilities, business, operations or prospects of the Company, that has not been set forth herein or heretofore communicated to Buyer in writing.

2.7. Legal Proceedings; Compliance with Laws. There are no lawsuits, proceeding, arbitrations or governmental investigations or audits pending or, to the knowledge of Sellers, threatened against, relating to or affecting any Seller with respect to the Business or any of the Company Assets. Sellers are not, nor have they at any time within the last three years been, in violation of or in default under any law applicable to the Business or the Company Assets, which violation is material to the ordinary conduct of its business.

2.8 Contracts. There are no material contracts to which either Seller is a party that are related to the Business or by which any of the Company Assets is bound.


2.9 Intellectual Property.

(a) Seller owns all technology required to conduct the Business as it is conducted by Seller as of the Effective Date (including without limitation all products, tools, computer programs, specifications, source code, object code, graphics, devices, techniques, algorithms, methods, processes, procedures, packaging, trade dress, formulae, drawings, designs, improvements, discoveries, concepts, user interfaces, software, "look and feel," development and other tools, content, inventions (whether or not patentable or copyrightable and whether or not reduced to practice), designs, logos, know-how and concepts).

(b) Seller has not received any notice or claim (whether written, oral or otherwise) challenging Seller's ownership or rights in the Company Assets or claiming that any other person or entity has any legal or beneficial ownership with respect thereto or challenging the validity or enforceability of the Company Assets. To the Seller's knowledge, no other person or entity is infringing or misappropriating the Company Assets.

(c) The Company Assets do not infringe, violate or interfere with or constitute a misappropriation of any right, title or interest (including, without limitation, any patent, copyright, trademark or trade secret right) held by any other person or entity, and there have been no claims made with respect thereto and (ii) Seller has not received any notice or claim (whether written, oral or otherwise) regarding any infringement, misappropriation, misuse, abuse or other interference with any third party intellectual property or proprietary rights (including, without limitation, infringement of any patent, copyright, trademark or trade secret right of any third party) by Seller or the Company Assets, or claiming that any other entity has any claim of infringement with respect thereto.

For purposes of this Section 2.9, it is understood that (i) no improvements on the Fractal Genomics Technology, nor any other or new technology, created by Buyer (with or without Shaw's assistance) shall be deemed an infringement or other violation of the foregoing representations and (ii) nothing contained herein shall be construed to assure the ultimate outcome of the patent applications or any of the claims therein (regardless of whether any or all of said claims are allowed or disallowed).

2.10 Entire Business. The sale of the Company Assets by Seller to Buyer pursuant to this Agreement will effectively convey to Buyer the entire Business and all of the tangible and intangible assets and property used by Seller (whether owned, leased or held under license by Seller, by any of Seller's affiliates or by others) in connection with the conduct of the Business as heretofore conducted by Seller. The Company Assets listed on Schedule 1.3 constitute all of the assets necessary to conduct the Business as currently conducted and as proposed to be conducted.

2.11 Securities Law Matters.

(a) Company will acquire the Buyer common stock for its own account for the purpose of investment and not with a view to or for sale in connection with any distribution thereof, and Company has no present intention or plan to effect any distribution thereof (other than to its members in connection with the dissolution of Company).

(b) Company is capable of evaluating the merits and risks of its investment in Buyer and has the capacity to protect its own interests. Company is aware that the acquisition of Buyer stock involves substantial risk and that its financial condition and investments are such that it is in a financial position to hold such securities for an indefinite period of time and to bear the economic risk of and withstand a complete loss of such investment.

E 58


(c) Company acknowledges that the Buyer stock must be held indefinitely unless subsequently registered under the Securities Act or an exemption from such registration is available. Company is aware of the provisions of Rule 144 promulgated under the Securities Act which permit the limited resale of securities issued in a private placement subject to the satisfaction of certain conditions.

(d) Company has had an opportunity to ask questions of management concerning Buyer and its business and to conduct its own independent due diligence investigation of Buyer.

ARTICLE 3. REPRESENTATIONS AND WARRANTIES OF BUYER

As an inducement to Seller to enter into and perform this Agreement, and in consideration of the covenants of Seller contained herein, Buyer represents and warrants to Seller, which representations and warranties shall survive the Closing, as follows:

3.1 Existence; Good Standing. Buyer is a corporation duly incorporated, validly existing, and in good standing under the laws of the State of Texas and in each jurisdiction where either the conduct of its business or ownership of its properties requires qualification to do business.

3.2 Authority. The Buyer has the requisite power and authority necessary to execute and deliver this Agreement, and the agreements contemplated hereby, and to perform its obligations hereunder and thereunder. The execution and delivery of this Agreement and all other documents contemplated hereby by Buyer, and the consummation by it of the transactions contemplated hereby, have been duly authorized by all requisite corporate action.

3.3 Enforceability. This Agreement, together with the documents contemplated hereby, and the Shaw Employment Agreement, each when executed and delivered, constitute, the valid and legally binding obligations of Buyer enforceable in accordance with their terms, except that enforceability may be limited by applicable bankruptcy, insolvency, or other similar laws of general application now or hereafter in effect relating to the enforcement of creditors' rights generally and by principles of equity (whether in a proceeding at law or in equity).

3.4 No Consents or Breaches. The execution and delivery of this Agreement by Buyer does not, and the consummation of the transactions contemplated hereby by Buyer will not (i) require the consent, approval or authorization of, or declaration, filing or registration with, any governmental or regulatory authority (except for filings required under applicable federal and state securities laws and stock exchange or NASDAQ rules); (ii) result in the breach of any material term or provision of, or constitute a material default under, or result in the acceleration of or entitle any party to accelerate (whether after the giving of notice or the lapse of time or both) any material obligation under, or result in the creation or imposition of any lien, charge, pledge, security interest or other encumbrance upon any part of the property of the Company pursuant to any provision of, any indenture, mortgage, lease, license, franchise, permit, authorization, lien, trust, or other agreement or instrument to which Seller or the Company is bound; (iii) violate or conflict with any provision of Buyer's organizational documents, as amended to the date hereof; or (iv) result in the violation of any statute, rule, regulation, ordinance, code, order, judgment, writ, injunction, decree, or arbitration award, or an event which with notice, lapse of time or both, would result in any such violation.


3.5 Broker's or Consultant's Fees. Buyer represents and warrants that it has dealt with no broker, finder or similar consultant in connection with the transaction contemplated by this Agreement, and, consequently, that no commission or finder's fee is due or payable in connection herewith.

3.6 No Untrue Statement. No representation or warranty of Buyer contained herein nor any written information, exhibits, schedules or agreements furnished by or on behalf of Buyer pursuant to this Agreement or in connection with the transaction contemplated herein contains or shall contain any untrue statement of a material fact, or omit or shall omit to state a material fact necessary to make the statements and facts contained therein not misleading. There is no fact known to Buyer which materially adversely affects, or in the future may materially adversely affect, individually or in the aggregate, the condition (financial or otherwise), assets, liabilities, business, operations or prospects of Buyer, that has not been set forth herein or heretofore communicated to Buyer in writing.

3.7 Capitalization. The authorized capital stock of the Buyer consists of 200,000,000 shares of no par value common stock, of which 59,751,128 shares are issued and outstanding as of October 1, 2003. Except as set forth on Schedule 3.7: (i) no options, warrants, subscriptions, puts, calls or other rights, commitments, undertakings or understandings granted by the Buyer to acquire, dispose of or restrict the transfer of, any of the Buyer's capital stock or other securities of any kind or class or rights, obligations or undertakings convertible into securities of any kind or class of the Buyer are authorized or outstanding; (ii) the Buyer is not subject to any obligation to purchase, redeem or otherwise acquire any of its capital stock or securities (or of any options or rights or obligations described in the preceding clause (i)) upon the occurrence of a specified event (and assuming that specified time periods have passed and appropriate notices have been given) or otherwise and
(iii) no other kind or class of capital stock except as described in this
Section 3.7 is authorized or outstanding. The shares of Buyer common stock issued and delivered to the Company as described in Section 1.2, and upon delivery of the Company Assets as provided in this Agreement, are duly authorized, validly issued, fully paid and nonassessable and not subject to preemptive rights created by statute, the Buyer's Articles of Incorporation or bylaws or any agreement to which Buyer is a party or is bound.

3.8 Financial Statements. The financial statements of Buyer contained in its public filings made with the Securities and Exchange Commission (i) have been prepared from and in accordance with the books and records of Buyer and in conformity with United States generally accepted accounting principles, consistently applied, in effect at the date of such financial statement ("GAAP") and (ii) such financial statements present fairly in accordance with GAAP the consolidated financial position and results of operations and cash flows of Buyer as of their respective dates and for the respective periods covered thereby.

3.9 Absences of Undisclosed Liabilities. Except as and to the extent reflected in or reserved against in the Buyer's financial statements, the Buyer has no other liabilities of any nature (whether accrued, absolute, contingent, changing, known, unknown, determinable, indeterminable, liquidated, unliquidated or otherwise and whether due or to become due) relating to any existing or prior act, omission, condition or state of facts, other than (a) liabilities incurred in the ordinary course of business or (b) liabilities which in the aggregate are not material to the condition of the Buyer's business.


3.10 Litigation. The Buyer (a) is not (and since December 31, 2002 has not been) engaged in, a party to, subject to or, to its knowledge, threatened with any claim, controversy, legal or equitable action or other proceeding (whether as plaintiff, defendant or otherwise); and (b) is not (and since December 31, 2002 has not been) a party to or subject to any judgment, order, decree or restriction against it.

3.11 Compliance with Laws. The Buyer is in compliance with all applicable law, including that involving antitrust, unfair competition, trade regulation, securities antipollution, environmental, employment and plant downsizing, relocation, closing or safety (except for instances of non-compliance that could not, in the aggregate, be reasonably expected to have a material adverse effect on the assets owned, leased or currently used by the Buyer or on the Buyer's business, financial condition or results of operations). The Buyer is not (and since December 31, 2002 has not been) either charged with, in receipt of any notice of, or, to its knowledge, under investigation with respect to any material failure or alleged material failure to comply with any provision of any applicable law that has had or that could be reasonably expected to have a material adverse effect on the assets owned, leased or currently used by the Buyer or on the Buyer's business, financial condition or results of operations.

3.12 Change in Control Provisions. Except as disclosed on Schedule 3.12, the Buyer is not a party nor subject to any agreement that contains any provisions that become effective or are accelerated or contingent upon a change in control of the Buyer or otherwise require any payment or performance by the Buyer or any officer, director or shareholder thereof, now or in the future, in connection with or as a result of any of the transactions contemplated by this Agreement.

ARTICLE 4. [INTENTIONALLY OMITTED.]

ARTICLE 5. [INTENTIONALLY OMITTED.]

ARTICLE 6. INDEMNIFICATION; SURVIVAL OF REPRESENTATIONS AND WARRANTIES.

6.1 Survival of Representations and Warranties and Indemnity Obligations. Notwithstanding any right of Buyer (whether or not exercised) to investigate the Business or any right of any party (whether or not exercised) to investigate the accuracy of the representations and warranties of the other party contained in this Agreement, Buyer has the right to rely fully upon the representations and warranties of Sellers contained in this Agreement. All representations and warranties made by the Parties in this Agreement and the indemnification obligations contained in this Article 6 shall survive the execution hereof and the Effective Date, and shall survive until the expiration of a period of one year after the date of this Agreement, except that any representation or warranty that would otherwise terminate will continue to survive if an indemnification notice shall have been timely given under on or prior to such termination date, until the related claim for indemnification has been satisfied or otherwise resolved.

6.2 Losses. "Losses" shall mean, for purposes of this Article 6, with respect to any person or party, any loss, liability, obligation, damage (including, without limitation, consequential, punitive, special or otherwise), deficiency, lien, claim, suit, cause of action, judgment, cost or expense (including, without limitation, reasonable attorneys' and accountants' fees and expenses and court costs of any kind, nature or description (regardless of whether the claim or threat of lawsuit matures into a lawsuit)).

6.3 Indemnification by Seller. Subject to the provisions of this Article 6, Seller, jointly and severally, shall indemnify, defend, protect, save and hold harmless Buyer and its officers, directors, employees and agents ("Seller Indemnified Parties") against, and will


reimburse Buyer and/or any of the aforementioned indemnitees on demand for, any and all Losses made or incurred by or asserted against any of the Seller Indemnified Parties, at any time after the Effective Date, directly or indirectly, arising out of, related to, caused by, or resulting from any of the following ("Seller Indemnified Claims"):

(a) any inaccuracy or misrepresentation in, omission from, or breach or nonfulfillment of, any representation, warranty, term, provision, or covenant by any Seller contained in this Agreement, or in any Schedule or Exhibit hereto.

6.4 Indemnification by Buyer. Subject to the provisions of this Article 6, Buyer shall indemnify, defend, protect, save and hold harmless each Seller and their officers, directors, employees and agents ("Buyer Indemnified Parties" and with the Seller Indemnified Parties, the "Indemnified Parties") against, and will reimburse such Buyer Indemnified Parties on demand for, any and all Losses made or incurred by or asserted against any of the Buyer Indemnified Parties, at any time after the Effective Date, directly or indirectly, arising out of, related to, caused by, or resulting from any of the following ("Buyer Indemnified Claims"):

(a) any inaccuracy, omission, misrepresentation in, omission from, or breach of nonfulfillment of any representation, warranty, term, provision, covenant or agreement on the part of Buyer contained in this Agreement or in any Schedule or Exhibit hereto.

6.5 Limitation on Liability. Notwithstanding the forgoing, the Indemnifying Party's obligations to indemnify the Indemnified Party against any Loss shall be subject to the following limitations:

(a) Threshold. No indemnification shall be made under Section 6.3 or 6.4 until the aggregate amount of Loss exceeds $25,000.00 (the "Threshold"), but if the aggregate amount of Loss thereunder exceeds $25,000.00, then indemnification shall be made by the Indemnifying Party thereunder for only such amounts as may exceed the $25,000.00 Threshold.

(b) Ceiling. Neither Company's nor Buyer's aggregate indemnification obligations under Section 6.3 or Section 6.4 shall exceed $500,000.00. Shaw's indemnification obligations under Section 6.3, whether arising directly or indirectly as a derivative claim through the Company, shall be limited to 51% of any Losses claimed and/or required and, in the aggregate, shall not exceed $255,000 (51% of $500,000).

6.6 Fraud; Intentional Misrepresentation, etc. The limitations set forth in Section 6.5 shall not apply to any Loss arising out of (i) fraud, (ii) the breach of any representation or warranty contained herein or pursuant hereto if such representation or warranty was made with actual knowledge that it contained an untrue statement of a fact or omitted to state a fact necessary to make the statements of facts contained therein not misleading, (iii) the breach of any representation or warranty contained in Section 2.10 or (iv) any failure by Sellers to timely pay, perform and discharge the Retained Liabilities.

6.7 Tax Adjustments. If a party's indemnification obligation under
Section 6.3 or Section 6.4 arises in respect of any indemnifiable event (a) for which an Indemnified Party receives indemnification and (b) which results in any tax benefit to such Indemnified Party for any taxable period (or portion thereof) which would not, but for such indemnifiable event, be available, such Indemnified Party shall pay, or shall cause to be paid, to the indemnifying party an amount equal to the actual tax saving produced by such tax benefit reduced by the amount of any tax detriment to such Indemnified Party as a result of the receipt of such indemnification.


Tax benefits and detriments shall be taken into account as and when actually realized. The amount of any such tax saving for any taxable period shall be the amount of the reduction in taxes payable to a tax authority by such Seller Party with respect to such tax period (net of any tax detriment resulting from the receipt of the indemnity payment) as compared to the taxes that would have been payable to a tax authority by such Indemnified Party with respect to such tax period in the absence of such tax benefit.

6.8 No Right of Offset. Notwithstanding any other provision hereof, until an arbitral award or court decision is rendered with respect to any disputed claims for indemnification hereunder, no offset or withholding shall be made or permitted with respect to any payments to be made to Sellers hereunder or with respect to any salaries or other compensation to be paid for services by Sandy Shaw.

6.9 No Right of Indemnification or Contribution. Notwithstanding anything contained herein to the contrary, under no circumstances shall either Seller have any right of indemnification or contribution against Buyer or Stephen D. Barnhill, M.D., in their respective capacities as members of Company. In the event of any conflict between this Section 6.9 and the Company's Operating Agreement, this Section 6.9 shall control.

Article 7. Miscellaneous.

7.1 Notices. Any notice, consent, approval, request, demand, declaration or other communication required hereunder shall be in and shall be given and shall be deemed to have been received if (i) delivered in person with receipt acknowledged, (ii) telecopied and electronically confirmed during regular business hours of recipient at recipient's place of business, and if sent outside of regular business hours, such notice is deemed given on the next business day, (iii) delivered by a nationally recognized overnight courier for next business day delivery with receipt acknowledged, or (iv) four days after being placed in the federal mail, postage prepaid, certified or registered mail, return receipt requested.

7.2 Binding Effect; Benefits. This Agreement shall be binding upon and shall inure to the benefit of the Parties, the Indemnified Parties, and their respective successors and permitted assigns. Notwithstanding anything contained herein to the contrary, nothing in this Agreement, expressed or implied, is intended to confer on any person (other than the Parties, the Indemnified Parties, or their respective successors and permitted assigns) any rights, remedies, obligations or liabilities under or by reason of this Agreement.

7.3 No Third-party Beneficiaries. No person or entity not a Party to this Agreement (other than the Indemnified Parties) shall be deemed to be a third-party beneficiary hereunder or entitled to any rights hereunder.

7.4 Entire Agreement; Amendment. This Agreement, together with the Exhibits, Schedules and other agreements and documents contemplated hereby, constitute the final written expression of all agreements between the Parties, and is a complete and exclusive statement of those terms. Except as specifically included or referred herein, this Agreement and the Exhibits, Schedules and other agreements and documents contemplated hereby supersede all prior understandings, negotiations and agreements concerning the matters specified herein, including without limitation the Letter Agreement, dated August 29, 2003, between Seller and Buyer. Any representations, promises, warranties or statements made by any Party that differ in any way from the terms of this written Agreement, and the Exhibits, Schedules and other agreements and documents contemplated hereby, shall be given no force or effect (except as specifically included


or referred to herein). The Parties specifically represent, each to the others, that there are no additional or supplemental agreements between them related in any way to the matters herein contained unless specifically included or referred to herein. No addition to or modification of any provision hereof shall be binding upon any Party unless made in writing and signed by all Parties.

7.5 Governing Law. THIS AGREEMENT, AND ALL QUESTIONS RELATING TO ITS VALIDITY, INTERPRETATION, PERFORMANCE AND ENFORCEMENT (INCLUDING, WITHOUT LIMITATION, PROVISIONS CONCERNING LIMITATIONS OF ACTION), SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF TEXAS (EXCLUSIVE OF THE CONFLICT OF LAW PROVISIONS THEREOF) APPLICABLE TO AGREEMENTS MADE AND TO BE PERFORMED ENTIRELY WITHIN SUCH STATE.

7.6 Venue; Binding Arbitration. PURSUANT TO THE FEDERAL ARBITRATION
ACT, ALL DISPUTES ARISING OUT OF OR RELATED TO THIS AGREEMENT, INCLUDING BUT NOT LIMITED TO DISPUTES REGARDING THE VALIDITY OF THIS PROVISION, SHALL BE SUBMITTED EXCLUSIVELY TO BINDING ARBITRATION, AT A LOCATION TO BE DETERMINED BY THE AMERICAN ARBITRATION ASSOCIATION PURSUANT TO THE COMMERCIAL ARBITRATION RULES OF THE AMERICAN ARBITRATION ASSOCIATION, PROVIDED HOWEVER THAT A PARTY SHALL BE ENTITLED TO SEEK INJUNCTIVE RELIEF FROM A COURT OF JURISDICTION AGAINST BREACH HEREOF OR IN AID OF ARBITRATION. THE PARTIES UNDERSTAND THAT THE AGREEMENT TO ARBITRATE CONSTITUTES A WAIVER OF TRIAL BY JURY. THE PREVAILING PARTY IN ANY ARBITRATION SHALL BE ENTITLED TO ENFORCEMENT OF THE ARBITRAL AWARD IN ANY COURT OF COMPETENT JURISDICTION.

7.7 Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be deemed an original but all of which shall constitute one and the same instrument.

7.8 Headings. Headings of the Sections and Articles of this Agreement are for the convenience of reference only, and shall be given no substantive or interpretive effect whatsoever.

7.9 Waivers. No wavier of any provision of this Agreement shall be valid or binding unless it is in writing, dated subsequent to the date hereof and signed by all Parties. No waiver of any breach, term or condition of this Agreement by any Party shall constitute a subsequent waiver of the same or any other breach, term or condition.

7.10 Severability. If for any reason whatsoever, any one or more of the provisions hereof shall be held or deemed to be illegal, inoperative, unenforceable or invalid, such determination shall not render any of the other provisions hereof illegal, inoperative, unenforceable or invalid, but this Agreement shall be construed as if such illegal, inoperative, unenforceable or invalid provisions had never been contained herein.

7.11 Assignability. Neither this Agreement nor any of the Parties' rights hereunder may be assigned by any Party without the prior written consent of the other Parties.


7.12 Construction. The Parties acknowledge that their respective attorneys have participated jointly in the drafting of this Agreement and that it has not been written solely by counsel for one Party. The Parties agree that the rule of construction to the effect that any ambiguities are to be or may be resolved against the drafting party shall not be employed in the interpretation of this Agreement to favor any Party against another.

7.13 Attorneys' Fees. The prevailing Party in any dispute between or among the Parties arising out of the interpretation, application or enforcement of any provision hereof shall be entitled to recover its reasonable attorneys' fees and costs whether suit be filed or not, including without limitation costs and attorneys' fees related to or arising out of any, trial or appellate proceedings.

7.14 Expenses. Except as specifically provided herein, each Party shall pay all of its own costs and expenses incurred or to be incurred in negotiating and preparing this Agreement and in effecting and carrying out the transactions contemplated hereby.

7.15 Further Actions. At any time and from time to time after the Effective Date, each Party hereto agrees, at its own expense (except as otherwise provided herein), to take such actions and to execute, acknowledge and deliver such documents as may be reasonably requested by another Party to effectuate the purposes of this Agreement.

ARTICLE 8. RESTRICTIVE COVENANTS.

8.1 Covenants of Sellers. In order to induce Buyer to enter into this Agreement and consummate the transactions contemplated hereby, each Seller agrees that neither it nor any of its respective affiliates shall, for a period to and including December 31, 2005, without the prior written consent of Buyer, directly or indirectly, for or on behalf of any person or entity, except for the benefit of the Buyer or its affiliates:

(a) engage or invest in, or own, control, manage or participate in the ownership, control or management of, or render services or advice to, any business engaged, or which it reasonably knows is undertaking to become engaged, in the development of Fractal Genomics Technology (more specifically, the business based upon and relating to the assets transferred hereunder) in the United States (the "Restricted Territory"); provided, that, Shaw shall not be prohibited by this subsection (a) from seeking or obtaining employment with any public or private company with annual sales in excess of $100 million or any non-profit corporation;

(b) solicit, or assist in the solicitation of, any person employed by the Buyer (as an employee, independent contractor or otherwise) within the Restricted Territory, to terminate such employment, whether or not such employment is pursuant to a contract and whether or not such employment is at will; or

(c) use, disclose or reveal to any person or entity, any Confidential Information (as defined below); provided, however, that the obligations of this clause (c) shall continue indefinitely with respect to any business information that constitutes a trade secret under applicable law. "Confidential Information" means all information of the Buyer related to the Business which derives value, economic or otherwise, from not being generally known to the public, but excluding any information that comes into the public domain through no fault of Sellers. The foregoing, however, shall not apply to any information which is required to be disclosed pursuant to law or by a legal process.


8.2 Equitable Relief. Notwithstanding anything contained in this Agreement to the contrary, Sellers acknowledge and agree that Buyer's remedy at law for a breach or threatened breach of any of the provisions of Section 8.1 would be inadequate and, in recognition of that fact, in the event of a breach or threatened breach by Seller of the provisions of Sections 8.1, it is agreed that, in addition to its remedies at law, Buyer shall be entitled to equitable relief in the form of specific performance, temporary restraining order, temporary, preliminary, or permanent injunction, or any other equitable remedy which may then be available, including but not limited to an equitable accounting of all earnings, profits and other benefits arising from or in connection with such violation. Sellers agree not to oppose Buyer's request for any of the above relief on the grounds that Buyer has not been irreparably injured or that Buyer has an adequate remedy at law or that such equitable relief is inappropriate. Nothing set forth in this Section 8.2 shall be construed as prohibiting Buyer from pursuing any other rights and remedies available to it for such breach or threatened breach.

8.3 Definition of Affiliate. As used herein, the term "Affiliate" means any person or entity that directly, or indirectly through one of more intermediaries, controls or is controlled by or is under common control with the person or entity specified. For purposes of this definition, control of a person or entity means the power, direct or indirect, to direct or cause the direction of the management and policies of such person or entity whether by contract or otherwise and, in any event and without limitation of the previous sentence, any person or entity owning ten percent (10%) or more of the voting securities of another person or entity shall be deemed to control that person or entity.

8.4 Termination. All of the foregoing covenants under this Article 8 will terminate as of January 1, 2006 or, earlier, in the event of a notice of reversion given pursuant to and in compliance with the terms of Section 1.2.5 herein.


IN WITNESS WHEREOF, the Parties have caused this Agreement to be duly executed as of the Effective Date.

BUYER:

HEALTH DISCOVERY CORPORATION

By: /s/  Stephen D. Barnhill
    ------------------------
    Stephen D. Barnhill M.D.
    Chief Executive Officer

COMPANY:

FRACTAL GENOMICS, LLC,
A California limited Liability Company

By: /s/ Sandy Shaw
    --------------
    Sandy Shaw
    Manager

SHAW:

/s/ Sandy Shaw
--------------
Sandy Shaw


SCHEDULE 1.3

ASSETS

All of the assets of Fractal Genomics, LLC (other than Seller's Retained Assets, as defined in Section 1.4), and as sold and transferred hereunder, consist of:

1. USPTO Patent Application serial no. 09/766,247 entitled "A Method for the Manipulation, Storage, Modeling, Visualization and Quantification of Datasets" filed January 19, 2001.

2. USPTO application serial no. 60/486,233, entitled "A Method for Pathway Conjecture and Diagnosis Using Fractal Modeling," filed July 10, 2003.

3. USPTO application serial no. 60/499,630 entitled "A Method for Identifying Fundamental Pathways Involved in Cellular Chronomics," filed September 2, 2003.

4. To the extent relating to the foregoing patent applications and rights and/or to the subject business to be conducted in connection with them, all written materials, web-based materials, software, including all source, object, and executable code in any form, and other intellectual and intangible property, and including (to the extent such so relate to said business):

(i) "Universal Modeling of Complex Networks", 2002.

(i) "Inverse Modeling of Complex Networks Using Complex Logistic Maps", 2002.

(iii) "Evidence of Scale-Free Topology and Dynamics in Gene Regulatory Networks", 2002. (Published in Proceedings of the ISCA 12th International Conference, Intelligent and Adaptive Systems and Software Engineering, pp. 37-40, 2003.)

(iv) "Fractal Modeling of Information Transmission within a Gene Regulatory Network: A New Approach to Pathway Conjecture and Diagnosis", 2003.

(v) All trade name and trademark rights in the name "Fractal Genomics" and all rights in the domain name "fractalgenomics.com".

For purposes of this Agreement, the term "Fractal Genomics Technology" means all of the technology and proprietary rights as set forth above, and the term "Business" means the business and business activities conducted (and to be conducted) in relation to said Fractal Genomics Technology.


SCHEDULE 2.6

Fractal Genomics, LLC is a high-risk, startup venture with no revenue. It intends to operate in a highly competitive market and compete against companies with greater financial and other resources. Initially, it will have negative operating income and may never become profitable. As a result, any financial projections are inherently uncertain and unreliable.


SCHEDULE 3.7

CAPITALIZATION

------------------------------------------------------
                         NO. OF SHARES SUBJECT TO
         NAME              OPTION/WARRANT GRANT
------------------------------------------------------
David Cooper                     2,400,000
------------------------------------------------------
David Cooper                      600,000
------------------------------------------------------
Joe Fanelli                      1,900,000
------------------------------------------------------
Joe Fanelli                       600,000
------------------------------------------------------


EXHIBIT 23

DARILEK, BUTLER & CO., P.C.
2702 N Loop 1604 East Suite 202
San Antonio, Texas 78232
210-979-0055 phone
210-979-0058 fax

CONSENT OF INDEPENDENT CERTIFIED PUBLIC ACCOUNTANTS

We consent to (a) the inclusion, in the Annual Report of Direct Wireless Communications, Inc. on Form 10-KSB, of our report dated February 27, 2004, relating to the financial statements of Direct Wireless Communications, Inc. for the year ended December 31, 2003 and the period from inception (April 6, 2001) to December 31, 2003.

"Darilek, Butler & Co., P.C."

San Antonio, Texas
February 27, 2004


EXHIBIT 31

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Robert S. Braswell IV, certify that:

1. I have reviewed this annual report on Form 10-K of Health Discovery Corporation formerly Direct Wireless Communications Inc.;

2. Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this annual report;

3. Based on my knowledge, the financial statements, and other financial information included in this annual report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this annual report;

4. The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the registrant and have:

a) designed such disclosure controls and procedures to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this annual report is being prepared;

b) evaluated the effectiveness of the registrant's disclosure controls and procedures as of a date within 90 days prior to the filing date of this annual report (the "Evaluation Date"); and

c) presented in this annual report our conclusions about the effectiveness of the disclosure controls and procedures based on our evaluation as of the Evaluation Date;

5. The registrant's other certifying officers and I have disclosed, based on our most recent evaluation, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):

a) all significant deficiencies in the design or operation of internal controls which could adversely affect the registrant's ability to record, process,


summarize and report financial data and have identified for the registrant's auditors any material weaknesses in internal controls; and

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal controls; and

6. The registrant's other certifying officers and I have indicated in this annual report whether or not there were significant changes in internal controls or in other factors that could significantly affect internal controls subsequent to the date of our most recent evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses.

Date: March 29, 2004

/s/ Robert S. Braswell IV
--------------------------------
Robert S. Braswell IV
Chief Administrative Officer


EXHIBIT 32

CERTIFICATION OF CHIEF FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350

In connection with the form 10-K of Health Discovery Corporation formerly Direct Wireless Communications Inc. for the Year ended December 31, 2003, I, Robert S. Braswell IV, Chief Administrative Officer of Direct Wireless, hereby certify pursuant to 18 U.S.C. ss.1350, as adopted pursuant to ss.906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge and belief, that;

such Form 10-K for the year ended, December 31, 2003, fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and the information contained in such Form 10-QSB for the year ended, fairly presents, in all material respects, the financial condition and results of operation of Health Discovery Corporation.

/s/ Robert S. Braswell IV
----------------------------------
Robert S. Braswell IV
Chief Administrative Officer